{"parse":{"title":"Herpes simplex research","pageid":35349626,"revid":856675445,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Herpes simplex research</b> includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of <a href=\"/wiki/Herpes_simplex\" title=\"Herpes simplex\">herpes</a>. Examples of particular herpes research include drug development, vaccines and genome editing.  HSV-1 and HSV-2 are commonly thought of as oral and genital herpes respectively, but other members in the herpes family include <a href=\"/wiki/Chickenpox\" title=\"Chickenpox\">chickenpox</a> (varicella/zoster), <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a> (CMV), and <a href=\"/wiki/Epstein-Barr\" class=\"mw-redirect\" title=\"Epstein-Barr\">Epstein-Barr</a> (EBV).\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Vaccine_research\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Vaccine research</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Vaccine_candidate\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Vaccine candidate</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Attenuated_vaccines\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Attenuated vaccines</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-4\"><a href=\"#Live,_attenuated_variant_of_the_HSV-2_vaccine\"><span class=\"tocnumber\">2.1.1</span> <span class=\"toctext\">Live, attenuated variant of the HSV-2 vaccine</span></a></li>\n<li class=\"toclevel-3 tocsection-5\"><a href=\"#Replication-defective_HSV-2_vaccine\"><span class=\"tocnumber\">2.1.2</span> <span class=\"toctext\">Replication-defective HSV-2 vaccine</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Glycoprotein_gD-_and_DNA-based_vaccines\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Glycoprotein gD- and DNA-based vaccines</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-7\"><a href=\"#Admedus&#39;s_vaccine\"><span class=\"tocnumber\">2.2.1</span> <span class=\"toctext\">Admedus's vaccine</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Other_vaccine_exploration\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">Other vaccine exploration</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Discontinued_vaccines\"><span class=\"tocnumber\">2.4</span> <span class=\"toctext\">Discontinued vaccines</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-10\"><a href=\"#Detailed_Information_on_discontinued_vaccines\"><span class=\"tocnumber\">2.4.1</span> <span class=\"toctext\">Detailed Information on discontinued vaccines</span></a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Genome_editing\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Genome editing</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#Notable_research\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Notable research</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-13\"><a href=\"#Herpes_simplex_virus\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Herpes simplex virus</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#Pharmaceutical_drugs\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Pharmaceutical drugs</span></a></li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Notable_progress\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">Notable progress</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-16\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Vaccine_research\">Vaccine research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=1\" title=\"Edit section: Vaccine research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Various vaccine candidates have been developed, the first ones in the 1920s, but none has been successful to date.<sup id=\"cite_ref-pmid22548113_1-0\" class=\"reference\"><a href=\"#cite_note-pmid22548113-1\">&#91;1&#93;</a></sup>\n</p><p>Due to the genetic similarity of both <a href=\"/wiki/Herpes_simplex_virus\" title=\"Herpes simplex virus\">herpes simplex virus</a> types (HSV-1 and HSV-2), the development of a prophylactic-therapeutic vaccine that proves effective against one type of the virus would likely prove effective for the other virus type, or at least provide most of the necessary fundamentals. As of  2016<sup class=\"plainlinks noexcerpt noprint asof-tag update\" style=\"display:none;\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Herpes_simplex_research&amp;action=edit\">&#91;update&#93;</a></sup>, several vaccine candidates are in different stages of clinical trials.\n</p><p>An ideal herpes vaccine should induce immune responses adequate to prevent infection. Short of this ideal, a candidate vaccine might be considered successful if it (a) mitigates primary clinical episodes, (b) prevents colonization of the <a href=\"/wiki/Ganglia\" class=\"mw-redirect\" title=\"Ganglia\">ganglia</a>, (c) helps reduce the frequency or severity of recurrences, and (d) reduces <a href=\"/wiki/Viral_shedding\" title=\"Viral shedding\">viral shedding</a> in actively infected or asymptomatic individuals.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup> The fact that a live, attenuated vaccine induced better protection from HSV infection and symptoms is not new, because live-attenuated vaccines account for most of the successful vaccines in use today. However, governmental and corporate bodies seem to support the more recent and safer but possibly less effective approaches such as Glycoprotein and DNA based vaccines.\n</p>\n<h2><span class=\"mw-headline\" id=\"Vaccine_candidate\">Vaccine candidate</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=2\" title=\"Edit section: Vaccine candidate\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The chart below is an attempt to list all known proposed vaccines and their characteristics. Please update with any missing information on vaccines only.\n</p>\n<table class=\"wikitable\" style=\"text-align: center;\">\n\n<tbody><tr>\n<th style=\"width:20%;background:#silver\">Vaccine\n</th>\n<th style=\"width:20%;background:rgb(100%,50%,80%);\">Company &amp; Lead Researcher\n</th>\n<th style=\"width:20%;background:rgb(80%,50%,80%);\">Vaccine Type\n</th>\n<th style=\"width:20%;background:rgb(70%,50%,80%);\"><a href=\"/wiki/Phases_of_clinical_research\" title=\"Phases of clinical research\">Status</a>\n</th>\n<th style=\"width:20%;background:rgb(90%,50%,80%);\">Trial Results\n</th></tr>\n<tr>\n<th>HSV-2 ICP0\u203e HSV-2 0\u0394NLS<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Rational_Vaccines&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Rational Vaccines (page does not exist)\">Rational Vaccines</a> RVx, William Halford<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>\n</td>\n<td>Live, Attenuated Interferon Sensitive\n</td>\n<td>Phase I\n</td>\n<td>About 65% of the patients reported being free of symptoms. Detailed results data is expected in late 2017.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> Currently embroiled in patient consent controversy.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</td></tr>\n<tr>\n<th>dl5-29 / ACAM-529 / HSV-529\n</th>\n<td><a href=\"/wiki/Sanofi_Pasteur\" title=\"Sanofi Pasteur\">Sanofi Pasteur</a>, David Knipe<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</td>\n<td>Live, Attenuated HSV-2 Replication-Defective vaccine with UL5 and UL29 deleted\n</td>\n<td>Phase I\n</td>\n<td>HSV529 was safe, well-tolerated, immunogenic, eliciting significant neutralizing gD and ADCC-mediating antibodies. Modest cellular immune responses were observed only in HSV seronegative individuals.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup>\n</td></tr>\n<tr>\n<th><a href=\"/w/index.php?title=Admedus&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Admedus (page does not exist)\">Admedus</a> HSV-2 therapeutic vaccine<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Admedus&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Admedus (page does not exist)\">Admedus</a>, <a href=\"/wiki/Ian_Frazer\" title=\"Ian Frazer\">Ian Frazer</a>\n</td>\n<td>DNA vaccine: codon optimized\n</td>\n<td>Phase II\n</td>\n<td>58% Reduction in Viral Shedding, 81% Reduction in Outbreaks (post-booster). The booster further reduced both the outbreaks and the shedding, suggesting an ongoing trend with subsequent boosters. Vaccine is being progressed.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</td></tr>\n<tr>\n<th>HSV Non-Invasive Vaccine\n</th>\n<td>Thyreos LLC<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n<p>Gregory Smith, Gary Pickard, &amp; Ekaterina Heldwein\n</p>\n</td>\n<td>Live, Attenuated HSV lacking neuroinvasive properties\n<p>(UL37 R2 mutated)\n</p>\n</td>\n<td>Preclinical\n</td>\n<td>Prevents HSV from entering the nervous system, establishing life-long infection, and causing disease in mice.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</td></tr>\n<tr>\n<th>HSV-2 \u0394gD-2\n</th>\n<td><a href=\"/wiki/Albert_Einstein_College_of_Medicine\" title=\"Albert Einstein College of Medicine\">Albert Einstein College of Medicine</a>, William R. Jacobs Jr &amp; Betsy C. Harold\n</td>\n<td>Live, Attenuated HSV-2 vaccine with US6 (gD) deleted\n</td>\n<td>Preclinical\n</td>\n<td>Successful in combating HSV-1 and HSV-2 in mice<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup>\n</td></tr>\n<tr>\n<th>HSV-2 Trivalent Vaccine<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>\n</th>\n<td><a href=\"/wiki/Perelman_School_of_Medicine_at_the_University_of_Pennsylvania\" title=\"Perelman School of Medicine at the University of Pennsylvania\">Perelman School of Medicine at the University of Pennsylvania</a>, Dr. Sita Awasthi\n</td>\n<td>HSV-2 Subunit Trivalent Vaccine (gC2, gD2, gE2)\n</td>\n<td>Preclinical\n</td>\n<td>Reduced shedding to 0.2% in animals<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\n</td></tr>\n<tr>\n<th>G103<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Immune_Design&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Immune Design (page does not exist)\">Immune Design</a>\n</td>\n<td>HSV-2 Subunit Trivalent Vaccine (gD, UL19, UL25)\n</td>\n<td>Preclinical\n</td>\n<td>Prophylactic immunization completely protected against lethal intravaginal HSV-2 infection in mice<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup>\n</td></tr>\n<tr>\n<th>GV2207<sup id=\"cite_ref-auto1_19-0\" class=\"reference\"><a href=\"#cite_note-auto1-19\">&#91;19&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=GenVec&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"GenVec (page does not exist)\">GenVec</a>\n</td>\n<td>?\n</td>\n<td>Preclinical<sup id=\"cite_ref-auto1_19-1\" class=\"reference\"><a href=\"#cite_note-auto1-19\">&#91;19&#93;</a></sup>\n</td>\n<td>?\n</td></tr>\n<tr>\n<th><a href=\"/w/index.php?title=Vitaherpavac&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vitaherpavac (page does not exist)\">Vitaherpavac</a> &amp; <a href=\"/w/index.php?title=Herpovax&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Herpovax (page does not exist)\">Herpovax</a>\n</th>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td></tr>\n<tr>\n<th>NE-HSV2<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup>\n</th>\n<td>NanoBio<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup>\n</td>\n<td>?\n</td>\n<td>Preclinical\n</td>\n<td>?\n</td></tr>\n<tr>\n<th>TBA<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Profectus_BioSciences&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Profectus BioSciences (page does not exist)\">Profectus BioSciences</a>\n</td>\n<td>DNA\n</td>\n<td>Antigen Discovery Stage\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th>Biomedical Research Models\n</th>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td></tr>\n<tr>\n<th><a href=\"/w/index.php?title=Tomegavax&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tomegavax (page does not exist)\">Tomegavax</a>\n</th>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td>\n<td>?\n</td></tr>\n<tr>\n<th><a href=\"/wiki/Zostavax\" class=\"mw-redirect\" title=\"Zostavax\">Zostavax</a>\n<p>(VZV, shingles)\n</p>\n</th>\n<td><a href=\"/wiki/Merck_%26_Co.\" title=\"Merck &amp; Co.\">Merck &amp; Co.</a>\n</td>\n<td>Live, Attenuated. This is primarily a vaccine focusing on <a href=\"/wiki/Varicella_zoster_virus\" title=\"Varicella zoster virus\">Varicella zoster virus</a>, not <a href=\"/wiki/Herpes_simplex_virus\" title=\"Herpes simplex virus\">Herpes simplex virus</a>.\n</td>\n<td>In Production\n</td>\n<td>Vaccination showed an immune response of 70% in 50 years old adults. The effectiveness went down to approx 64% in 60 years old, 41% in 70 years old, and 18% in 80 years old individuals.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</td></tr>\n<tr>\n<th><a href=\"/wiki/Varivax\" class=\"mw-redirect\" title=\"Varivax\">Varivax</a>,<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> Varilrix<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> (Varicella, C.Pox)\n</th>\n<td><a href=\"/wiki/Merck_%26_Co.\" title=\"Merck &amp; Co.\">Merck &amp; Co.</a>, <a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a>\n</td>\n<td>Live, Attenuated. This is primarily a vaccine focusing on <a href=\"/wiki/Varicella_zoster_virus\" title=\"Varicella zoster virus\">Varicella zoster virus</a>, not <a href=\"/wiki/Herpes_simplex_virus\" title=\"Herpes simplex virus\">Herpes simplex virus</a>.\n</td>\n<td>In Production\n</td>\n<td>One dose of vaccine prevents 95% of moderate disease and 100% of severe disease.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup>\n</td></tr>\n<tr>\n<th><a href=\"/wiki/Shingrix\" class=\"mw-redirect\" title=\"Shingrix\">Shingrix</a>, GSK1437173A\n<p>(VZV, shingles)\n</p>\n</th>\n<td><a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a>\n</td>\n<td>Sub Unit gE with AS01B/<a href=\"/wiki/QS21\" title=\"QS21\">QS-21</a> adjuvant system.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-nature.com_28-0\" class=\"reference\"><a href=\"#cite_note-nature.com-28\">&#91;28&#93;</a></sup> This is primarily a vaccine against <a href=\"/wiki/Varicella_zoster_virus\" title=\"Varicella zoster virus\">Varicella zoster virus</a>, not <a href=\"/wiki/Herpes_simplex_virus\" title=\"Herpes simplex virus\">Herpes simplex virus</a>.\n</td>\n<td>In Production<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup>\n</td>\n<td>Vaccination produced a strong immune response in adults 65 and older. Final trials results reported an effectiveness of 90% in the first year which went down slightly to 88%, four years after vaccination.<sup id=\"cite_ref-Loyd_2017_30-0\" class=\"reference\"><a href=\"#cite_note-Loyd_2017-30\">&#91;30&#93;</a></sup>\n</td></tr>\n</tbody></table>\n<h3><span class=\"mw-headline\" id=\"Attenuated_vaccines\">Attenuated vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=3\" title=\"Edit section: Attenuated vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:287px;\"><a href=\"/wiki/File:HalfordsVac.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/61/HalfordsVac.jpg/285px-HalfordsVac.jpg\" width=\"285\" height=\"136\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/6/61/HalfordsVac.jpg 1.5x\" data-file-width=\"354\" data-file-height=\"169\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:HalfordsVac.jpg\" class=\"internal\" title=\"Enlarge\"></a></div>Depiction shows mice who were vaccinated with two different vaccine candidates, then are exposed to a common wild-type HSV strain usually found in humans. A generic subunit gD vaccine does confer only weak protection, with 1 of 4 mice surviving after a month. The effect of Halford's HSV-2 ICP0 vaccine, achieving sterilizing immunity in vaccinated mice with 5 of 5 mice surviving after a month.</div></div></div>\n<h4><span id=\"Live.2C_attenuated_variant_of_the_HSV-2_vaccine\"></span><span class=\"mw-headline\" id=\"Live,_attenuated_variant_of_the_HSV-2_vaccine\">Live, attenuated variant of the HSV-2 vaccine</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=4\" title=\"Edit section: Live, attenuated variant of the HSV-2 vaccine\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Diverse subunit HSV vaccines (e.g. <a href=\"/wiki/Herpevac\" class=\"mw-redirect\" title=\"Herpevac\">Herpevac</a>) have failed to protect humans from acquiring genital herpes in several clinical trials. The success of the <a href=\"/wiki/Varicella_vaccine\" title=\"Varicella vaccine\">chickenpox vaccine</a> demonstrates that a live and appropriately attenuated <a href=\"/wiki/Alphaherpesvirinae\" title=\"Alphaherpesvirinae\">\u03b1-herpesvirus</a> may be used to safely control human disease. A vaccine of this type would present a slow replication process of HSV, thereby also damping down the immune evasion strategies of the virus while simultaneously exposing the host to the full complement of HSV's majority of viral proteins. As a consequence, it is the intent of the vaccine to expose the individual's immune response to the HSV proteins it may have been missing from a wild type virus in order to effectively control the disease. From a historical retrospective, such live attenuated vaccines have had the most success in preventing diseases until today. Dr. William Halford at the <a href=\"/wiki/Southern_Illinois_University_School_of_Medicine\" title=\"Southern Illinois University School of Medicine\">Southern Illinois University (SIU) School of Medicine</a> was testing a live-attenuated HSV-2 ICP0\u203e vaccine in 2016, before his death in June, 2017.<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup><sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> Already proven as safe and effective in studies on animals, eliciting 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine, Halford's vaccine has been tested outside of the United States, in St. Kitts and is expecting a 2018 test in Australia.<sup id=\"cite_ref-34\" class=\"reference\"><a href=\"#cite_note-34\">&#91;34&#93;</a></sup>\n</p><p>In 2016 Halford had promising results injecting his vaccine in 20 human volunteers, 17 of which got all 3 shots, (the other 3, only 2 shots).  All 20 of the participants self-reported an improvement in symptoms, but only 17 received and completed all three dosages.<sup id=\"cite_ref-Bloom_2018_35-0\" class=\"reference\"><a href=\"#cite_note-Bloom_2018-35\">&#91;35&#93;</a></sup>  Blot tests showed a clear antibody response, which cannot be instigated by a placebo effect.\n</p>\n<h4><span class=\"mw-headline\" id=\"Replication-defective_HSV-2_vaccine\">Replication-defective HSV-2 vaccine</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=5\" title=\"Edit section: Replication-defective HSV-2 vaccine\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:290px;\"><a href=\"/wiki/File:HSV529.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/HSV529.png/288px-HSV529.png\" width=\"288\" height=\"83\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/HSV529.png/432px-HSV529.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/4c/HSV529.png/576px-HSV529.png 2x\" data-file-width=\"688\" data-file-height=\"198\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:HSV529.png\" class=\"internal\" title=\"Enlarge\"></a></div>Principle of HSV529</div></div></div>\n<p><a href=\"/wiki/David_M._Knipe\" title=\"David M. Knipe\">David M. Knipe</a>, a Professor at <a href=\"/wiki/Harvard_Medical_School\" title=\"Harvard Medical School\">Harvard Medical School</a> has developed <i>dl</i>5-29. The <i>dl</i>5-29 vaccine is also known under the name ACAM-529<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup> or HSV-529, a replication-defective vaccine that has proved successful in preventing both HSV-2 and HSV-1 infections and in combating the virus in already-infected hosts, in animal models.<sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup> The HSV-529 is a leading vaccine candidate which has been investigated in numerous research publications, and is endorsed by many researchers in the field (i.a. Lynda A. Morrison and Jeffrey Cohen).<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup>  It has also been shown that the vaccine induces strong HSV-2-specific <a href=\"/wiki/Antibody\" title=\"Antibody\">antibody</a> and <a href=\"/wiki/T-cell\" class=\"mw-redirect\" title=\"T-cell\">T-cell</a> responses, protects against challenge with a wild-type HSV-2 virus, reduces the severity of recurrent disease, provides cross-protection against HSV-1.<sup id=\"cite_ref-39\" class=\"reference\"><a href=\"#cite_note-39\">&#91;39&#93;</a></sup> The ongoing trials would prove if a durable immune response in humans is to be successfully achieved or if the vaccine is too over attenuated to do the same. The vaccine is now being researched and developed by <a href=\"/wiki/Sanofi_Pasteur\" title=\"Sanofi Pasteur\">Sanofi Pasteur</a>.<sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup> Both Sanofi Pasteur and the clinical-stage immunotherapy company <a href=\"/w/index.php?title=Immune_Design&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Immune Design (page does not exist)\">Immune Design</a> have entered a broad collaboration, which will explore the potential of various combinations of agents against HSV-2, including an adjuvanted trivalent vaccine candidate G103, consisting of recombinantly-expressed viral proteins.<sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup>\n</p><p>HSV-529 has concluded phase I clinical trials in March 2017.<sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Glycoprotein_gD-_and_DNA-based_vaccines\">Glycoprotein gD- and DNA-based vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=6\" title=\"Edit section: Glycoprotein gD- and DNA-based vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<h4><span id=\"Admedus.27s_vaccine\"></span><span class=\"mw-headline\" id=\"Admedus's_vaccine\">Admedus's vaccine</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=7\" title=\"Edit section: Admedus&#039;s vaccine\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Professor <a href=\"/wiki/Ian_Frazer\" title=\"Ian Frazer\">Ian Frazer</a> developed an <a rel=\"nofollow\" class=\"external text\" href=\"http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0076407\">experimental vaccine</a> with his team at <a href=\"/w/index.php?title=Coridon_(company)&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Coridon (company) (page does not exist)\">Coridon</a>, a biotechnology company he founded in 2000. The company, now known under the name <a href=\"/w/index.php?title=Admedus_Vaccines&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Admedus Vaccines (page does not exist)\">Admedus Vaccines</a>, is researching DNA technology for vaccines with prophylactic and therapeutic potential. What's different about this vaccine is the way that response is being created. Instead of introducing a weakened version of the herpes virus, this vaccine uses a small section of DNA to produce T-cells and stimulate the immune response.<sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup> The new vaccine candidate is designed to prevent new infections, and to treat those who already have the infection. In February 2014, it was announced that Frazer's new vaccine against genital herpes has passed human safety trials in a trial of 20 Australians.<sup id=\"cite_ref-44\" class=\"reference\"><a href=\"#cite_note-44\">&#91;44&#93;</a></sup> In October 2014, Admedus announced success in creating a positive T-cell response in 95% of participants.<sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup> Further research is required to determine if the vaccine can prevent transmission. In July 2014, Admedus increased its stake in Frazer's vaccines by 16.2%. In addition, $18.4 million was posted as funds raised towards Phase II vaccine testing and research.<sup id=\"cite_ref-46\" class=\"reference\"><a href=\"#cite_note-46\">&#91;46&#93;</a></sup>\n</p><p>The HSV-2 Phase II trial began in April 2015.<sup id=\"cite_ref-47\" class=\"reference\"><a href=\"#cite_note-47\">&#91;47&#93;</a></sup>  Interim results were published on March 4, 2016 and based on the results of a scheduled, blinded, pooled analysis of data from the first 20 patients to receive at least three vaccinations in the randomised, placebo controlled Phase II study with the following results:\n</p>\n<ul><li>No safety issues have been noted in this cohort of patients. The data remains blinded to protect the integrity of the trial.</li>\n<li>Study participants had a marked decrease in viral lesions (outbreaks) with a drop of over 90% in the monthly rate versus baseline.</li>\n<li>The average number of days HSV-2 was detected in patients was reduced versus baseline.</li></ul>\n<p>On 19 October 2016, Admedus released interim results from the ongoing HSV-2 Phase IIa study.  The unblinded data demonstrated a 58% reduction in viral shedding compared to baseline and a reduction in outbreaks of 52% post vaccination and 81% overall reduction post-booster.<sup id=\"cite_ref-48\" class=\"reference\"><a href=\"#cite_note-48\">&#91;48&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other_vaccine_exploration\">Other vaccine exploration</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=8\" title=\"Edit section: Other vaccine exploration\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>A study from the <a href=\"/wiki/Albert_Einstein_College_of_Medicine\" title=\"Albert Einstein College of Medicine\">Albert Einstein College of Medicine</a>, where glycoprotein D (gD-2) was deleted from the herpes cell, showed positive results when tested in mice.<sup id=\"cite_ref-49\" class=\"reference\"><a href=\"#cite_note-49\">&#91;49&#93;</a></sup> Researchers deleted gD-2 from the herpes virus, which is responsible for herpes microbes entering in and out of cells. The vaccine is still in early stages of development and more research needs to be conducted before receiving FDA approval for clinical trials.<sup id=\"cite_ref-50\" class=\"reference\"><a href=\"#cite_note-50\">&#91;50&#93;</a></sup>\n</p><p>Research conducted by the <a href=\"/w/index.php?title=NanoBio_Corporation&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"NanoBio Corporation (page does not exist)\">NanoBio Corporation</a> indicates that an enhanced protection from HSV-2 is a result of mucosal immunity which can be elicited by their intranasal nanoemulsion vaccine. NanoBio published results showing efficiency in studies conducted in both the prophylactic and the therapeutic guinea pig model. This included preventing infection and viral latency in 92% of animals vaccinated and a reduction in recurrent legions by 64% and viral shedding by 53%. NanoBio hopes to raise funds in 2016 to enter into Phase I clinical testing.<sup id=\"cite_ref-51\" class=\"reference\"><a href=\"#cite_note-51\">&#91;51&#93;</a></sup>\n</p><p><a href=\"/w/index.php?title=Profectus_BioSciences&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Profectus BioSciences (page does not exist)\">Profectus BioSciences</a> intends to use its PBS Vax therapeutic vaccine technology to engineer a vaccine for HSV-2.<sup id=\"cite_ref-52\" class=\"reference\"><a href=\"#cite_note-52\">&#91;52&#93;</a></sup> The vaccine is in early development and much is unknown about its viability.\n</p><p><a href=\"/w/index.php?title=Biomedical_Research_Models&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Biomedical Research Models (page does not exist)\">Biomedical Research Models</a>, a <a href=\"/wiki/Worcester\" title=\"Worcester\">Worcester</a>-based biopharmaceutical company has been awarded a fund for the development of a novel vaccine platform to combat mucosally transmitted pathogens such as HSV-2.<sup id=\"cite_ref-53\" class=\"reference\"><a href=\"#cite_note-53\">&#91;53&#93;</a></sup>\n</p><p>The company <a href=\"/w/index.php?title=Tomegavax&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tomegavax (page does not exist)\">Tomegavax</a> (recently acquired by <a href=\"/w/index.php?title=Vir_Biotechnology&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vir Biotechnology (page does not exist)\">Vir Biotechnology</a>)) is researching to utilize <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a> (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. It has been awarded a grant by the NIH for this purpose.<sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup>\n</p><p><a href=\"/w/index.php?title=Redbiotec&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Redbiotec (page does not exist)\">Redbiotec</a>, a privately held Swiss biopharmaceutical company, based in <a href=\"/wiki/Zurich\" class=\"mw-redirect\" title=\"Zurich\">Zurich</a> as a spin-off of the <a href=\"/wiki/ETH_Zurich\" title=\"ETH Zurich\">ETH Zurich</a>, is focusing on the development of a vaccine against HSV-2. Redbiotec's preclinical vaccine shows over 90% of lesion score (vs. approx. 50% for GEN-003 of Genocea) in early findings.<sup id=\"cite_ref-55\" class=\"reference\"><a href=\"#cite_note-55\">&#91;55&#93;</a></sup>\n</p><p>Scientists from Northwestern University, University of Nebraska-Lincoln and Tufts University have established a R2 HSV mutant, which can successfully infect epithelial cells, but the virus fails to infect neurons. Future research will focus on further developing the R2 mutant as a master herpes virus vaccine.<sup id=\"cite_ref-56\" class=\"reference\"><a href=\"#cite_note-56\">&#91;56&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Discontinued_vaccines\">Discontinued vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=9\" title=\"Edit section: Discontinued vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Below is a list of vaccines that are no longer being pursued.\n</p>\n<table class=\"wikitable\" style=\"text-align: center;\">\n\n<tbody><tr>\n<th style=\"width:20%;background:#silver\" colspan=\"2\">Vaccine\n</th>\n<th style=\"width:20%;background:rgb(100%,50%,80%);\">Organization\n</th>\n<th style=\"width:20%;background:rgb(80%,50%,80%);\">Vaccine Type\n</th>\n<th style=\"width:20%;background:rgb(70%,50%,80%);\">Reason\n</th>\n<th style=\"width:20%;background:rgb(90%,50%,80%);\">Final Results\n</th></tr>\n<tr>\n<th colspan=\"2\">Herpevac, Simplirix\n</th>\n<td><a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a>\n</td>\n<td>Prophylactic, Sub Unit gD2t with alum/MPL adjuvant <a href=\"/wiki/AS04\" title=\"AS04\">AS04</a><sup id=\"cite_ref-57\" class=\"reference\"><a href=\"#cite_note-57\">&#91;57&#93;</a></sup><sup id=\"cite_ref-nature.com_28-1\" class=\"reference\"><a href=\"#cite_note-nature.com-28\">&#91;28&#93;</a></sup>\n</td>\n<td>Failed in Phase III clinical trial<sup id=\"cite_ref-58\" class=\"reference\"><a href=\"#cite_note-58\">&#91;58&#93;</a></sup>\n</td>\n<td>No statistically significant results found<sup id=\"cite_ref-ReferenceA_59-0\" class=\"reference\"><a href=\"#cite_note-ReferenceA-59\">&#91;59&#93;</a></sup>\n</td></tr>\n<tr>\n<th colspan=\"2\">Unnamed<sup id=\"cite_ref-60\" class=\"reference\"><a href=\"#cite_note-60\">&#91;60&#93;</a></sup>\n</th>\n<td><a href=\"/wiki/PaxVax\" title=\"PaxVax\">PaxVax</a>\n</td>\n<td>Recombinant Vector Vaccine<sup id=\"cite_ref-61\" class=\"reference\"><a href=\"#cite_note-61\">&#91;61&#93;</a></sup>\n</td>\n<td>Discontinued in pre-clinical stage, no longer appears in company's pipeline<sup id=\"cite_ref-paxvax.com_62-0\" class=\"reference\"><a href=\"#cite_note-paxvax.com-62\">&#91;62&#93;</a></sup>\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th colspan=\"2\">ImmunoVEX HSV2 vaccine\n</th>\n<td><a href=\"/wiki/Amgen\" title=\"Amgen\">Amgen</a>, <a href=\"/w/index.php?title=BioVex&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"BioVex (page does not exist)\">BioVex</a>\n</td>\n<td>Live, Attenuated, defective in immune evasion<sup id=\"cite_ref-63\" class=\"reference\"><a href=\"#cite_note-63\">&#91;63&#93;</a></sup>\n</td>\n<td>Discontinued in Phase I stage, no longer appears in company's pipeline<sup id=\"cite_ref-Amgen_Pipeline_64-0\" class=\"reference\"><a href=\"#cite_note-Amgen_Pipeline-64\">&#91;64&#93;</a></sup>\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th colspan=\"2\">Gen-003\n</th>\n<td><a href=\"/w/index.php?title=Genocea&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Genocea (page does not exist)\">Genocea</a>\n</td>\n<td>Sub Unit gD2/ICP4 with Matrix M2 adjuvant\n</td>\n<td>Discontinued after Phase II stage\n</td>\n<td>58% Reduction in Viral Shedding, 69% Reduction in Outbreaks. Spending on vaccine has ceased.<sup id=\"cite_ref-65\" class=\"reference\"><a href=\"#cite_note-65\">&#91;65&#93;</a></sup>\n</td></tr>\n<tr>\n<th colspan=\"2\">AuRx Herpes Vaccine\n</th>\n<td><a href=\"/w/index.php?title=AuRx&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AuRx (page does not exist)\">AuRx</a><sup id=\"cite_ref-66\" class=\"reference\"><a href=\"#cite_note-66\">&#91;66&#93;</a></sup>\n</td>\n<td>Recombinant Vector Vaccine<sup id=\"cite_ref-67\" class=\"reference\"><a href=\"#cite_note-67\">&#91;67&#93;</a></sup>\n</td>\n<td>Inactive\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th colspan=\"2\">DISC vaccine<sup id=\"cite_ref-68\" class=\"reference\"><a href=\"#cite_note-68\">&#91;68&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Cantab_Pharmaceuticals&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cantab Pharmaceuticals (page does not exist)\">Cantab Pharmaceuticals</a>\n</td>\n<td>Live, Attenuated HSV vaccine with gH deleted\n</td>\n<td>Discontinued in Phase I stage\n</td>\n<td>No clinical or virological benefit was shown\n</td></tr>\n<tr>\n<th colspan=\"2\">Unnamed<sup id=\"cite_ref-:0_69-0\" class=\"reference\"><a href=\"#cite_note-:0-69\">&#91;69&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Mymetics&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Mymetics (page does not exist)\">Mymetics</a>\n</td>\n<td>?\n</td>\n<td>Discontinued in pre-clinical stage, no longer appears in company's pipeline\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th colspan=\"2\">HerpV\n</th>\n<td><a href=\"/wiki/Agenus\" title=\"Agenus\">Agenus</a>\n</td>\n<td>Peptide vaccine/<a href=\"/wiki/QS21\" title=\"QS21\">QS-21</a> adjuvant\n</td>\n<td>Discontinued after Phase II stage<sup id=\"cite_ref-70\" class=\"reference\"><a href=\"#cite_note-70\">&#91;70&#93;</a></sup>\n</td>\n<td>N/A\n</td></tr>\n<tr>\n<th colspan=\"2\">VCL-HB01<sup id=\"cite_ref-71\" class=\"reference\"><a href=\"#cite_note-71\">&#91;71&#93;</a></sup>\n</th>\n<td><a href=\"/w/index.php?title=Vical&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vical (page does not exist)\">Vical</a>\n</td>\n<td>DNA vaccine: gD2+UL46/Vaxfectin adjuvant\n</td>\n<td>Discontinued after Phase II stage\n</td>\n<td>Trial did not show positive outcome.<sup id=\"cite_ref-vical.com_72-0\" class=\"reference\"><a href=\"#cite_note-vical.com-72\">&#91;72&#93;</a></sup>\n</td></tr>\n</tbody></table>\n<h4><span class=\"mw-headline\" id=\"Detailed_Information_on_discontinued_vaccines\">Detailed Information on discontinued vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=10\" title=\"Edit section: Detailed Information on discontinued vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>One vaccine that was under trial was <a href=\"/wiki/Herpevac\" class=\"mw-redirect\" title=\"Herpevac\">Herpevac</a>, a vaccine against HSV-2. The <a href=\"/wiki/National_Institutes_of_Health\" title=\"National Institutes of Health\">National Institutes of Health</a> (NIH) in the <a href=\"/wiki/United_States\" title=\"United States\">United States</a> conducted <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">phase III trials</a> of Herpevac.<sup id=\"cite_ref-autogenerated1_73-0\" class=\"reference\"><a href=\"#cite_note-autogenerated1-73\">&#91;73&#93;</a></sup>  In 2010, it was reported that, after 8 years of study in more than 8,000 women in the United States and Canada, there was no sign of positive results against the sexually transmitted disease caused by HSV-2<sup id=\"cite_ref-ReferenceA_59-1\" class=\"reference\"><a href=\"#cite_note-ReferenceA-59\">&#91;59&#93;</a></sup> (and this despite earlier favorable interim reports<sup id=\"cite_ref-autogenerated1_73-1\" class=\"reference\"><a href=\"#cite_note-autogenerated1-73\">&#91;73&#93;</a></sup>).\n</p><p><a href=\"/wiki/PaxVax\" title=\"PaxVax\">PaxVax</a>, a specialty vaccine company, partnered with Spector Lab at the <a href=\"/wiki/University_of_California,_San_Diego\" title=\"University of California, San Diego\">UC San Diego</a> Department of Cellular and Molecular Medicine regarding the development of a genital herpes <a href=\"/wiki/Viral_vector\" title=\"Viral vector\">viral vector</a> vaccine. The vaccine was in the pre-clinical stage.<sup id=\"cite_ref-74\" class=\"reference\"><a href=\"#cite_note-74\">&#91;74&#93;</a></sup> The vaccine is no longer listed on their website as a present endeavour and has likely been discontinued.<sup id=\"cite_ref-paxvax.com_62-1\" class=\"reference\"><a href=\"#cite_note-paxvax.com-62\">&#91;62&#93;</a></sup>\n</p><p>A private company called <a href=\"/w/index.php?title=BioVex&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"BioVex (page does not exist)\">BioVex</a> began Phase I clinical trials for <a href=\"/w/index.php?title=ImmunoVEX&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ImmunoVEX (page does not exist)\">ImmunoVEX</a>, another proposed vaccine, in March 2010.<sup id=\"cite_ref-75\" class=\"reference\"><a href=\"#cite_note-75\">&#91;75&#93;</a></sup> The Company had commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes. The biopharmaceutical company <a href=\"/wiki/Amgen\" title=\"Amgen\">Amgen</a> bought BioVex<sup id=\"cite_ref-76\" class=\"reference\"><a href=\"#cite_note-76\">&#91;76&#93;</a></sup> and their proposed ImmunoVEX vaccine appears to have been discontinued, furthermore it has been removed from the company's research pipeline.<sup id=\"cite_ref-Amgen_Pipeline_64-1\" class=\"reference\"><a href=\"#cite_note-Amgen_Pipeline-64\">&#91;64&#93;</a></sup>\n</p><p>A live, attenuated vaccine (which was proven very effective in clinical trials in Mexico) by the company <a href=\"/w/index.php?title=AuRx&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AuRx (page does not exist)\">AuRx</a> has failed to proceed to a Phase III trial in the year 2006, due to financial reasons. The AuRx therapy was shown to be safe and decrease the occurrence of lesions by 86% after one year.<sup id=\"cite_ref-77\" class=\"reference\"><a href=\"#cite_note-77\">&#91;77&#93;</a></sup>\n</p><p><a href=\"/w/index.php?title=Mymetics&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Mymetics (page does not exist)\">Mymetics</a> is developing a pre-clinical preventative vaccine for HSV 1 and 2 using its virosome technology.<sup id=\"cite_ref-:0_69-1\" class=\"reference\"><a href=\"#cite_note-:0-69\">&#91;69&#93;</a></sup> There has not been any recent announcement by the company regarding their vaccine, which seems to have been taken off from the company's research product pipeline.\n</p><p><a href=\"/w/index.php?title=HerpV&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"HerpV (page does not exist)\">HerpV</a>, a genital herpes vaccine candidate manufactured by the company <a href=\"/wiki/Agenus\" title=\"Agenus\">Agenus</a>, announced Phase II clinical trial results in June 2014. Results showed up to a 75% reduction in viral load and a weak reduction in viral shedding by 14%.<sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup> These results were achieved after a series of vaccinations and a booster dose after six months, signalling the vaccine may take time to become effective. Further testing results are to show if the vaccine is a viable candidate against genital herpes.<sup id=\"cite_ref-79\" class=\"reference\"><a href=\"#cite_note-79\">&#91;79&#93;</a></sup> There has not been any recent announcement by Agenus regarding the vaccine HerpV, which seems to have been taken off from the company's research product pipeline.<sup id=\"cite_ref-80\" class=\"reference\"><a href=\"#cite_note-80\">&#91;80&#93;</a></sup>\n</p><p><a href=\"/w/index.php?title=Genocea_Biosciences&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Genocea Biosciences (page does not exist)\">Genocea Biosciences</a> has developed GEN-003, a first-in-class protein subunit T cell-enabled therapeutic vaccine, or immunotherapy, designed to reduce the duration and severity of clinical symptoms associated with moderate-to-severe HSV-2, and to control transmission of the infection. GEN-003 includes the antigens <a href=\"/w/index.php?title=ICP4&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ICP4 (page does not exist)\">ICP4</a> and <a href=\"/wiki/GD2\" title=\"GD2\">gD2</a>, as well as the proprietary adjuvant Matrix-M. GEN-003 had concluded <a rel=\"nofollow\" class=\"external text\" href=\"http://www.clinicaltrials.gov/ct2/show/NCT02114060\">Phase IIa clinical trials</a>. In December 2015, Genocea announced <a rel=\"nofollow\" class=\"external text\" href=\"http://medicalresearch.com/author-interviews/first-therapeutic-vaccine-genital-herpes-shows-promise/22945/\">interim data</a> showing a 58% decrease in viral shedding and a 69% decrease in genital lesions. They also showed one of the doses stopped outbreaks for at least 6 months.<sup id=\"cite_ref-81\" class=\"reference\"><a href=\"#cite_note-81\">&#91;81&#93;</a></sup> GEN-003 was <a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/show/NCT02515175\">undergoing a Phase IIb clinical trial</a> in the United States. Genocea has announced it would shift their strategic efforts to cancer vaccines while at the same time heavily cutting down on research and development of GEN-003 vaccine against genital herpes.<sup id=\"cite_ref-82\" class=\"reference\"><a href=\"#cite_note-82\">&#91;82&#93;</a></sup> Being unable to secure funding or partnering with another company, Genocea's further vaccine development remains to be determined.\n</p><p><a href=\"/w/index.php?title=Vical&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vical (page does not exist)\">Vical</a> had been awarded grant funding from the National Institute of Allergy and Infectious Diseases division of the NIH to develop a  <a href=\"/wiki/Plasmid\" title=\"Plasmid\">plasmid</a> DNA-based vaccine to inhibit recurring lesions in patients latently infected with herpes simplex virus type 2 (HSV-2). The plasmid DNA encoding the HSV-2 antigens was formulated with <a href=\"/w/index.php?title=Vaxfectin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vaxfectin (page does not exist)\">Vaxfectin</a>, Vical's proprietary cationic lipid adjuvant. Vical is concluding <a rel=\"nofollow\" class=\"external text\" href=\"http://www.clinicaltrials.gov/ct/show/NCT02030301\">Phase I clinical trials</a>, while reporting data showing the vaccine candidate failed to meet the primary endpoint.<sup id=\"cite_ref-83\" class=\"reference\"><a href=\"#cite_note-83\">&#91;83&#93;</a></sup> The San Diego-based company was forced to concede that their herpes strategy had misfired, with their vaccine failing to perform as well as a placebo.<sup id=\"cite_ref-84\" class=\"reference\"><a href=\"#cite_note-84\">&#91;84&#93;</a></sup>  However, that seemed to may have changed, since 20 June 2016, when Vical released phase I/II results at <a href=\"/wiki/American_Society_for_Microbiology\" title=\"American Society for Microbiology\">ASM</a>.<sup id=\"cite_ref-85\" class=\"reference\"><a href=\"#cite_note-85\">&#91;85&#93;</a></sup> Their vaccine (named VCL-HB01) was involved in a <a rel=\"nofollow\" class=\"external text\" href=\"https://www.clinicaltrials.gov/ct/show/NCT02837575\">Phase II clinical trial</a>. The recent trial, similarly to a past trial again missed the primary endpoint and therefore the company is discontinuing the vaccine and moving to other pipeline products.<sup id=\"cite_ref-vical.com_72-1\" class=\"reference\"><a href=\"#cite_note-vical.com-72\">&#91;72&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Genome_editing\">Genome editing</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=11\" title=\"Edit section: Genome editing\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Another area of research for HSV treatment or a potential cure is the use of <a href=\"/wiki/Genome_editing\" title=\"Genome editing\">genome editing</a>. It is thought that by cleaving the DNA of HSV that infects neurons, thereby causing destruction or mutational inactivation of the HSV DNA, the virus can be greatly treated or even cured.<sup id=\"cite_ref-86\" class=\"reference\"><a href=\"#cite_note-86\">&#91;86&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Notable_research\">Notable research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=12\" title=\"Edit section: Notable research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a rel=\"nofollow\" class=\"external text\" href=\"http://research.fhcrc.org/jerome/en.html\">Jerome Lab</a> run by Dr. Keith Jerome at the <a href=\"/wiki/Fred_Hutchinson_Cancer_Research_Center\" title=\"Fred Hutchinson Cancer Research Center\">Fred Hutchinson Cancer Research Center</a> has looked at using <a href=\"/wiki/Zinc_finger_nuclease\" title=\"Zinc finger nuclease\">zinc finger nuclease</a> as well as <a href=\"/wiki/Endonuclease\" title=\"Endonuclease\">endonuclease</a> to prevent HSV from replicating. Most recently Dr. Jerome and his lab were able to demonstrate cleavage of latent HSV in a living organism, which is vital to disabling the virus.<sup id=\"cite_ref-87\" class=\"reference\"><a href=\"#cite_note-87\">&#91;87&#93;</a></sup> The lab is now looking at ways to better optimize the process, including using <a href=\"/wiki/CRISPR-Cas9\" class=\"mw-redirect\" title=\"CRISPR-Cas9\">CRISPR-Cas9</a>, with several years of work expected before clinical trials are considered.<sup id=\"cite_ref-88\" class=\"reference\"><a href=\"#cite_note-88\">&#91;88&#93;</a></sup>\n</p><p><a href=\"/wiki/Editas_Medicine\" title=\"Editas Medicine\">Editas Medicine</a>, that previously collaborated with the Cullen Lab,<sup id=\"cite_ref-89\" class=\"reference\"><a href=\"#cite_note-89\">&#91;89&#93;</a></sup> are researching <a href=\"/wiki/CRISPR-Cas9\" class=\"mw-redirect\" title=\"CRISPR-Cas9\">CRISPR-Cas9</a> for its use in <a href=\"/wiki/Herpes_Simplex_Keratitis\" class=\"mw-redirect\" title=\"Herpes Simplex Keratitis\">Herpes Simplex Keratitis</a>.\n</p><p>Researchers at <a href=\"/wiki/Temple_University\" title=\"Temple University\">Temple University</a> have been researching how to disrupt HSV from replicating that could eventually lead to a cure.<sup id=\"cite_ref-90\" class=\"reference\"><a href=\"#cite_note-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-91\" class=\"reference\"><a href=\"#cite_note-91\">&#91;91&#93;</a></sup> Some members of research team at Temple University have also joined forces to create Excision BioTheraputics. The company intends to begin clinical trials in 2019-2020.<sup id=\"cite_ref-92\" class=\"reference\"><a href=\"#cite_note-92\">&#91;92&#93;</a></sup>\n</p><p>Researchers at the <a href=\"/wiki/University_Medical_Center_Utrecht\" title=\"University Medical Center Utrecht\">University Medical Center Utrecht</a>, using the <a href=\"/wiki/CRISPR-Cas9\" class=\"mw-redirect\" title=\"CRISPR-Cas9\">CRISPR-Cas9</a> system, have showed promising results in clearing HSV-1 infection by simultaneously targeting multiple essential vital genes in vitro.<sup id=\"cite_ref-93\" class=\"reference\"><a href=\"#cite_note-93\">&#91;93&#93;</a></sup> The researchers are now looking at targeting latent HSV-1 genomes and are investigating in vivo model systems to assess the potential therapeutic application.<sup id=\"cite_ref-94\" class=\"reference\"><a href=\"#cite_note-94\">&#91;94&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Herpes_simplex_virus\">Herpes simplex virus</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=13\" title=\"Edit section: Herpes simplex virus\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>A research paper providing an overview of the relatively recent state of research can be found on <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencedirect.com/science/article/pii/S0264410X16002978\">this page</a>.\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmaceutical_drugs\">Pharmaceutical drugs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=14\" title=\"Edit section: Pharmaceutical drugs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Since the introduction of the nucleoside analogs decades ago, treatment of herpes simplex virus (HSV) infections has not seen much innovation, except for the development of their respective prodrugs (Aciclovir, Famciclovir, Valacilovir..). Drawbacks such as poor bioavailability or limited effectiveness of these drugs require further research effort of new pharmaceutical drugs against the herpes simplex disease. The inhibitors of the <a href=\"/wiki/Helicase-primase_complex\" class=\"mw-redirect\" title=\"Helicase-primase complex\">Helicase-primase complex</a> of HSV represent a very innovative approach to the treatment of herpesvirus disease.<sup id=\"cite_ref-95\" class=\"reference\"><a href=\"#cite_note-95\">&#91;95&#93;</a></sup> \n</p>\n<table class=\"wikitable\" style=\"text-align: center;\">\n\n<tbody><tr>\n<th style=\"width:20%;background:#silver\" colspan=\"2\">Pharmaceutical Drug\n</th>\n<th style=\"width:20%;background:rgb(100%,50%,80%);\">Company\n</th>\n<th style=\"width:20%;background:rgb(90%,50%,80%);\">Lead Researcher\n</th>\n<th style=\"width:20%;background:rgb(80%,50%,80%);\">Type\n</th>\n<th style=\"width:20%;background:rgb(70%,50%,80%);\">Status\n</th></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/wiki/Aciclovir\" title=\"Aciclovir\">Aciclovir</a>\n</th>\n<td>patents expired\n</td>\n<td>Schaeffer &amp; B. Elion\n</td>\n<td>nucleic acid analogue\n</td>\n<td>In Production\n</td></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/wiki/Valaciclovir\" title=\"Valaciclovir\">Valaciclovir</a>\n</th>\n<td>patents expired\n</td>\n<td>?\n</td>\n<td>nucleic acid analogue\n</td>\n<td>In Production\n</td></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/wiki/Famciclovir\" title=\"Famciclovir\">Famciclovir</a>\n</th>\n<td>patents expired\n</td>\n<td>?\n</td>\n<td>nucleic acid analogue\n</td>\n<td>In Production\n</td></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/wiki/Pritelivir\" title=\"Pritelivir\">Pritelivir</a>\n</th>\n<td>AICuris\n</td>\n<td>?\n</td>\n<td>helicase-primase inhibitor\n</td>\n<td>Phase II<sup id=\"cite_ref-96\" class=\"reference\"><a href=\"#cite_note-96\">&#91;96&#93;</a></sup>\n</td></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/wiki/Amenamevir\" title=\"Amenamevir\">Amenamevir</a>\n</th>\n<td>Astellas Pharma Inc\n</td>\n<td>Kiyomitsu Katsumata<sup id=\"cite_ref-97\" class=\"reference\"><a href=\"#cite_note-97\">&#91;97&#93;</a></sup>\n</td>\n<td>helicase-primase inhibitor\n</td>\n<td>In Production\n</td></tr>\n<tr>\n<th colspan=\"2\"><a href=\"/w/index.php?title=BX795&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"BX795 (page does not exist)\">BX795</a>\n</th>\n<td>?\n</td>\n<td>Deepak Shukla\n</td>\n<td>kinase inhibitor\n</td>\n<td>Preclinical\n</td></tr>\n</tbody></table>\n<h3><span class=\"mw-headline\" id=\"Notable_progress\">Notable progress</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=15\" title=\"Edit section: Notable progress\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Researchers have made a <a href=\"/wiki/Hammerhead_ribozyme\" title=\"Hammerhead ribozyme\">Hammerhead ribozyme</a> that targets and cleaves the mRNA of essential genes in HSV-1. The hammerhead, which targets the mRNA of the UL20 gene, greatly reduced the level of HSV-1 ocular infection in rabbits, and reduced the viral yield in vivo.<sup id=\"cite_ref-98\" class=\"reference\"><a href=\"#cite_note-98\">&#91;98&#93;</a></sup> The gene-targeting approach uses a specially designed RNA enzyme to inhibit strains of the herpes simplex virus. The enzyme disables a gene responsible for producing a protein involved in the maturation and release of viral particles in an infected cell. The technique appears to be effective in experiments with mice and rabbits, but further research is required before it can be attempted in people infected with herpes.<sup id=\"cite_ref-99\" class=\"reference\"><a href=\"#cite_note-99\">&#91;99&#93;</a></sup>\n</p><p>In 2016, researchers showed that the <a href=\"/wiki/Genome_editing\" title=\"Genome editing\">genome editing</a> technology known as <a href=\"/wiki/CRISPR\" title=\"CRISPR\">CRISPR</a>/Cas can be used to limit viral replication in multiple strains of herpesviruses, in some cases even eliminating the infection altogether.<sup id=\"cite_ref-100\" class=\"reference\"><a href=\"#cite_note-100\">&#91;100&#93;</a></sup> The researchers tested three different strains of herpesviruses: <a href=\"/wiki/Epstein-Barr_virus\" class=\"mw-redirect\" title=\"Epstein-Barr virus\">Epstein-Barr virus</a> (EBV), the cause of <a href=\"/wiki/Mononucleosis\" class=\"mw-redirect\" title=\"Mononucleosis\">mononucleosis</a> and some cancers; <a href=\"/wiki/Herpes_simplex_viruses\" class=\"mw-redirect\" title=\"Herpes simplex viruses\">Herpes simplex viruses</a> (HSV-1) and (HSV-2), which cause cold sores and genital herpes respectively; and <a href=\"/wiki/Human_cytomegalovirus\" title=\"Human cytomegalovirus\">Human cytomegalovirus</a> (HCMV), which causes congenital herpes.The results indicated that CRISPR can be used to eliminate replication in all three strains of the virus, but that the technology was so far only successful in actually eradicating EBV. The authors think this may be because the EBV genome is located in dividing cells that are easily accessible to CRISPR. Comparatively, the HSV-1 genome targeted by CRISPR is located in closed-off, non-replicating neurons, which makes reaching the genome much more challenging.<sup id=\"cite_ref-101\" class=\"reference\"><a href=\"#cite_note-101\">&#91;101&#93;</a></sup>\n</p><p>Another possibility to eradicate the HSV-1 variant is being pursued by a team at <a href=\"/wiki/Duke_University\" title=\"Duke University\">Duke University</a>. By figuring out how to switch all copies of the virus in the host from latency to their active stage at the same time, rather than the way the virus copies normally stagger their activity stage, leaving some dormant somewhere at all times, it is thought that immune system could kill the entire infected cell population, since they can no longer hide in the nerve cells.  This is a potentially risky approach especially for patients with widespread infections as there is the possibility of significant tissue damage from the immune response.  One class of drugs called <a href=\"/wiki/Antagomir\" title=\"Antagomir\">antagomir</a> could trigger reactivation. These are chemically engineered oligonucleotides or short segments of RNA, that can be made to mirror their target genetic material, namely herpes microRNAs. They could be engineered to attach and thus 'silence' the microRNA, thus rendering the virus incapable of keeping latent in their host.<sup id=\"cite_ref-102\" class=\"reference\"><a href=\"#cite_note-102\">&#91;102&#93;</a></sup> Professor Cullen believes a drug could be developed to block the microRNA whose job it is to suppress HSV-1 into latency.<sup id=\"cite_ref-103\" class=\"reference\"><a href=\"#cite_note-103\">&#91;103&#93;</a></sup>\n</p><p>Herpes has been used in research with <a href=\"/wiki/HeLa_cells\" class=\"mw-redirect\" title=\"HeLa cells\">HeLa cells</a> to determine its ability to assist in the treatment of <a href=\"/wiki/Malignant\" class=\"mw-redirect\" title=\"Malignant\">malignant</a> <a href=\"/wiki/Tumors\" class=\"mw-redirect\" title=\"Tumors\">tumors</a>. A study conducted using suicide gene transfer by a cytotoxic approach examined a way to eradicate malignant tumors.<sup id=\"cite_ref-Martin_104-0\" class=\"reference\"><a href=\"#cite_note-Martin-104\">&#91;104&#93;</a></sup> Gene therapy is based on the cytotoxic genes that directly or indirectly kill tumor cells regardless of its gene expression. In this case the study uses the transfer of the Herpes simplex virus type I thymidine kinase (HSVtk) as the cytotoxic gene. Hela cells were used in these studies because they have very little ability to communicate through <a href=\"/wiki/Gap_junctions\" class=\"mw-redirect\" title=\"Gap junctions\">gap junctions</a>.<sup id=\"cite_ref-Mesnil_105-0\" class=\"reference\"><a href=\"#cite_note-Mesnil-105\">&#91;105&#93;</a></sup> The Hela cells involved were grown in a monolayer culture and then infected with the HSV virus. The HSV mRNA was chosen because it is known to share characteristics with normal eukaryotic mRNA.<sup id=\"cite_ref-Stringer_106-0\" class=\"reference\"><a href=\"#cite_note-Stringer-106\">&#91;106&#93;</a></sup>\n</p><p>The HSVtk expression results in the <a href=\"/wiki/Phosphorylation\" title=\"Phosphorylation\">phosphorylation</a> of drug <a href=\"/wiki/Nucleoside\" title=\"Nucleoside\">nucleoside</a> analogues; in this case the drug ganciclovir, an anitiviral medication used to treat and prevent cytomegaloviruses, converts it into the nucleoside analogue triphosphates. Once granciclovir is phosphorylated through HSV-tk it is then incorporating DNA strands when the cancer cells are multiplying.<sup id=\"cite_ref-Mesnil_105-1\" class=\"reference\"><a href=\"#cite_note-Mesnil-105\">&#91;105&#93;</a></sup> The nucleotide from the ganciclovir is what inhibits the DNA polymerization and the replication process. This causes the cell to die via <a href=\"/wiki/Apoptosis\" title=\"Apoptosis\">apoptosis</a>.<sup id=\"cite_ref-Martin_104-1\" class=\"reference\"><a href=\"#cite_note-Martin-104\">&#91;104&#93;</a></sup> \n</p><p>Apoptosis is regulated with the help of <a href=\"/wiki/MiRNAs\" class=\"mw-redirect\" title=\"MiRNAs\">miRNAs</a>, which are small non-coding RNAs that negatively regulate gene expression.<sup id=\"cite_ref-Jovanovic_107-0\" class=\"reference\"><a href=\"#cite_note-Jovanovic-107\">&#91;107&#93;</a></sup> These miRNAs play a critical role in developing the timing, differentiation and cell death. The miRNAs effect on apoptosis has affected cancer development by the regulation of cell proliferation, as well as cell transformation.  Avoidance of apoptosis is critical for the success of malignant tumors, and one way for miRNAs to possibly influence cancer development is to regulate apoptosis. In order to support this claim, Hela cells were used for the experiment discussed.\n</p><p>The cytotoxic drug used, ganciclovir, is capable of destroying via apoptosis transduced cells and non-transduced cells from the cellular gap junction. This technique is known as the \"bystander effect,\" which has suggested to scientists that the effect of some therapeutic agents may be enhanced by <a href=\"/wiki/Diffusion\" title=\"Diffusion\">diffusion</a> through gap junctional <a href=\"/w/index.php?title=Intercellular&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Intercellular (page does not exist)\">intercellular</a> communication (GJIC) or cell coupling. GJIC is an important function in the maintaining of tissue homeostasis and it is a critical factor in balance of cells dying and surviving.\n</p><p>When Hela cells were <a href=\"/wiki/Transfected\" class=\"mw-redirect\" title=\"Transfected\">transfected</a> with the HSV-tk gene, and were then put in a culture with nontransfected cells, only the HSV-tk transfected Hela cells were killed by the granciclovir, leaving the nonviral cells unharmed.<sup id=\"cite_ref-Mesnil_105-2\" class=\"reference\"><a href=\"#cite_note-Mesnil-105\">&#91;105&#93;</a></sup>   The Hela cells were transfected with the encoding for the gap junction protenin <a href=\"/wiki/Connexin\" title=\"Connexin\">connexin</a> 43 (Cx43) to provide a channel that permits ions and other molecules to move between neighboring cells. Both Hela cells with the HSV-tk and without the HSV-tk were destroyed. This result has led to the evidence needed to state that the bystander effect in the HSV-tk gene therapy is possibly due to the Cx-mediated GJIC.\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Herpes_simplex_research&amp;action=edit&amp;section=16\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-pmid22548113-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid22548113_1-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L (2012). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3324142\">\"Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown\"</a>. <i>Clinical &amp; Developmental Immunology</i>. <b>2012</b>: 187585. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1155/2012/187585\">10.1155/2012/187585</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3324142\">3324142</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22548113\">22548113</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+%26+Developmental+Immunology&amp;rft.atitle=Towards+a+rational+design+of+an+asymptomatic+clinical+herpes+vaccine%3A+the+old%2C+the+new%2C+and+the+unknown&amp;rft.volume=2012&amp;rft.pages=187585&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3324142&amp;rft_id=info%3Apmid%2F22548113&amp;rft_id=info%3Adoi%2F10.1155%2F2012%2F187585&amp;rft.aulast=Chentoufi&amp;rft.aufirst=AA&amp;rft.au=Kritzer%2C+E&amp;rft.au=Yu%2C+DM&amp;rft.au=Nesburn%2C+AB&amp;rft.au=Benmohamed%2C+L&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3324142&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Whitley RJ, Roizman B (July 2002). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC151069\">\"Herpes simplex viruses: is a vaccine tenable?\"</a>. <i>The Journal of Clinical Investigation</i>. <b>110</b> (2): 145\u201351. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1172/JCI16126\">10.1172/JCI16126</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC151069\">151069</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12122103\">12122103</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Investigation&amp;rft.atitle=Herpes+simplex+viruses%3A+is+a+vaccine+tenable%3F&amp;rft.volume=110&amp;rft.issue=2&amp;rft.pages=145-51&amp;rft.date=2002-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC151069&amp;rft_id=info%3Apmid%2F12122103&amp;rft_id=info%3Adoi%2F10.1172%2FJCI16126&amp;rft.aulast=Whitley&amp;rft.aufirst=RJ&amp;rft.au=Roizman%2C+B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC151069&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://liveherpesvaccine.com/rational-vaccines-inc/\">\"Introducing RVx\"</a>. 2016-03-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-08-02</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Introducing+RVx&amp;rft.date=2016-03-12&amp;rft_id=https%3A%2F%2Fliveherpesvaccine.com%2Frational-vaccines-inc%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://liveherpesvaccine.com/\">\"Herpes Vaccine Research\"</a>. <i>Herpes Vaccine Research</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-08-02</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Herpes+Vaccine+Research&amp;rft.atitle=Herpes+Vaccine+Research&amp;rft_id=https%3A%2F%2Fliveherpesvaccine.com%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://medcitynews.com/2017/03/rational-vaccines-pharma-deregulation/\">\"Rational Vaccines: A case study in pharma deregulation - MedCity News\"</a>. <i>medcitynews.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 September</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=medcitynews.com&amp;rft.atitle=Rational+Vaccines%3A+A+case+study+in+pharma+deregulation+-+MedCity+News&amp;rft_id=http%3A%2F%2Fmedcitynews.com%2F2017%2F03%2Frational-vaccines-pharma-deregulation%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cnn.com/2018/04/23/health/fda-halford-herpes-vaccine-research/index.html\">\"FDA Launches Criminal Investigation Into Unauthorized Herpes Vaccine Research\"</a>. <i>khn.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-05-21</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=khn.org&amp;rft.atitle=FDA+Launches+Criminal+Investigation+Into+Unauthorized+Herpes+Vaccine+Research&amp;rft_id=https%3A%2F%2Fwww.cnn.com%2F2018%2F04%2F23%2Fhealth%2Ffda-halford-herpes-vaccine-research%2Findex.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://knipelab.med.harvard.edu/\">\"Knipe Lab | Harvard Medical School\"</a>. <i>knipelab.med.harvard.edu</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-08-02</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=knipelab.med.harvard.edu&amp;rft.atitle=Knipe+Lab+%7C+Harvard+Medical+School&amp;rft_id=http%3A%2F%2Fknipelab.med.harvard.edu%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lee YC (December 1967). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5630753\">\"Ventricular fusion beats\"</a>. <i>JAMA</i>. <b>202</b> (10): 991. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5630753\">5630753</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Ventricular+fusion+beats&amp;rft.volume=202&amp;rft.issue=10&amp;rft.pages=991&amp;rft.date=1967-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5630753&amp;rft.aulast=Lee&amp;rft.aufirst=YC&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5630753&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.admedus.com/au/technology/immunotherapies/\">\"Admedus AU Immunotherapies\"</a>. <i>www.admedus.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-01-18</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.admedus.com&amp;rft.atitle=Admedus+AU+Immunotherapies&amp;rft_id=http%3A%2F%2Fwww.admedus.com%2Fau%2Ftechnology%2Fimmunotherapies%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.admedus.com/us/health-solutions/research-development/\">\"Admedus US Research &amp; Development - Admedus US\"</a>. <i>www.admedus.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-08-02</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.admedus.com&amp;rft.atitle=Admedus+US+Research+%26+Development+-+Admedus+US&amp;rft_id=http%3A%2F%2Fwww.admedus.com%2Fus%2Fhealth-solutions%2Fresearch-development%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://clients2.weblink.com.au/news/pdf_1%5C01791053.pdf\">\"ADMEDUS ANNOUNCES POSITIVE UNBLINDED HSV-2 PHASE II INTERIM DATA\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Admedus</i>. 19 October 2016.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Admedus&amp;rft.atitle=ADMEDUS+ANNOUNCES+POSITIVE+UNBLINDED+HSV-2+PHASE+II+INTERIM+DATA&amp;rft.date=2016-10-19&amp;rft_id=http%3A%2F%2Fclients2.weblink.com.au%2Fnews%2Fpdf_1%255C01791053.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://news.feinberg.northwestern.edu/2017/12/herpes-virus-mutant-points-towards-new-vaccine-strategy/\">\"Herpes Virus Mutant Points Towards New Vaccine Strategy\"</a>. <i>news.feinberg.northwestern.edu</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-08-13</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=news.feinberg.northwestern.edu&amp;rft.atitle=Herpes+Virus+Mutant+Points+Towards+New+Vaccine+Strategy&amp;rft_id=https%3A%2F%2Fnews.feinberg.northwestern.edu%2F2017%2F12%2Fherpes-virus-mutant-points-towards-new-vaccine-strategy%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Richards AL, Sollars PJ, Pitts JD, Stults AM, Heldwein EE, Pickard GE, Smith GA (December 2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5749899\">\"The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion\"</a>. <i>PLoS Pathogens</i>. <b>13</b> (12): e1006741. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.ppat.1006741\">10.1371/journal.ppat.1006741</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5749899\">5749899</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/29216315\">29216315</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS+Pathogens&amp;rft.atitle=The+pUL37+tegument+protein+guides+alpha-herpesvirus+retrograde+axonal+transport+to+promote+neuroinvasion&amp;rft.volume=13&amp;rft.issue=12&amp;rft.pages=e1006741&amp;rft.date=2017-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5749899&amp;rft_id=info%3Apmid%2F29216315&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.ppat.1006741&amp;rft.aulast=Richards&amp;rft.aufirst=AL&amp;rft.au=Sollars%2C+PJ&amp;rft.au=Pitts%2C+JD&amp;rft.au=Stults%2C+AM&amp;rft.au=Heldwein%2C+EE&amp;rft.au=Pickard%2C+GE&amp;rft.au=Smith%2C+GA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5749899&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Petro CD, Weinrick B, Khajoueinejad N, Burn C, Sellers R, Jacobs WR, Herold BC (August 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://insight.jci.org/articles/view/88529\">\"HSV-2 \u0394gD elicits Fc\u03b3R-effector antibodies that protect against clinical isolates\"</a>. <i>JCI Insight</i>. <b>1</b> (12). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1172/jci.insight.88529\">10.1172/jci.insight.88529</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4985247\">4985247</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27536733\">27536733</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JCI+Insight&amp;rft.atitle=HSV-2+%CE%94gD+elicits+Fc%CE%B3R-effector+antibodies+that+protect+against+clinical+isolates&amp;rft.volume=1&amp;rft.issue=12&amp;rft.date=2016-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4985247&amp;rft_id=info%3Apmid%2F27536733&amp;rft_id=info%3Adoi%2F10.1172%2Fjci.insight.88529&amp;rft.aulast=Petro&amp;rft.aufirst=CD&amp;rft.au=Weinrick%2C+B&amp;rft.au=Khajoueinejad%2C+N&amp;rft.au=Burn%2C+C&amp;rft.au=Sellers%2C+R&amp;rft.au=Jacobs%2C+WR&amp;rft.au=Herold%2C+BC&amp;rft_id=http%3A%2F%2Finsight.jci.org%2Farticles%2Fview%2F88529&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.pennmedicine.org/news/news-releases/2017/january/new-genital-herpes-vaccine-candidate-provides-powerful-protection-in-preclinical-tests\">\"New Genital Herpes Vaccine Candidate Provides Powerful Protection in Preclinical Tests\"</a>. Penn Medicine News. 19 January 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">28 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=New+Genital+Herpes+Vaccine+Candidate+Provides+Powerful+Protection+in+Preclinical+Tests&amp;rft.pub=Penn+Medicine+News&amp;rft.date=2017-01-19&amp;rft_id=https%3A%2F%2Fwww.pennmedicine.org%2Fnews%2Fnews-releases%2F2017%2Fjanuary%2Fnew-genital-herpes-vaccine-candidate-provides-powerful-protection-in-preclinical-tests&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Awasthi S, Hook LM, Shaw CE, Pahar B, Stagray JA, Liu D, Veazey RS, Friedman HM (January 2017). <a rel=\"nofollow\" class=\"external text\" href=\"http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006141\">\"An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs\"</a>. <i>PLoS Pathogens</i>. <b>13</b> (1): e1006141. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.ppat.1006141\">10.1371/journal.ppat.1006141</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5245903\">5245903</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28103319\">28103319</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS+Pathogens&amp;rft.atitle=An+HSV-2+Trivalent+Vaccine+Is+Immunogenic+in+Rhesus+Macaques+and+Highly+Efficacious+in+Guinea+Pigs&amp;rft.volume=13&amp;rft.issue=1&amp;rft.pages=e1006141&amp;rft.date=2017-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5245903&amp;rft_id=info%3Apmid%2F28103319&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.ppat.1006141&amp;rft.aulast=Awasthi&amp;rft.aufirst=S&amp;rft.au=Hook%2C+LM&amp;rft.au=Shaw%2C+CE&amp;rft.au=Pahar%2C+B&amp;rft.au=Stagray%2C+JA&amp;rft.au=Liu%2C+D&amp;rft.au=Veazey%2C+RS&amp;rft.au=Friedman%2C+HM&amp;rft_id=http%3A%2F%2Fjournals.plos.org%2Fplospathogens%2Farticle%3Fid%3D10.1371%2Fjournal.ppat.1006141&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.immunedesign.com/pipeline/\">\"Immune Design Pipeline\"</a>. Immune Design<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 April</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Immune+Design+Pipeline&amp;rft.pub=Immune+Design&amp;rft_id=http%3A%2F%2Fwww.immunedesign.com%2Fpipeline%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Odegard JM, Flynn PA, Campbell DJ, Robbins SH, Dong L, Wang K, Ter Meulen J, Cohen JI, Koelle DM (January 2016). \"A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs\". <i>Vaccine</i>. <b>34</b> (1): 101\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.vaccine.2015.10.137\">10.1016/j.vaccine.2015.10.137</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26571309\">26571309</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Vaccine&amp;rft.atitle=A+novel+HSV-2+subunit+vaccine+induces+GLA-dependent+CD4+and+CD8+T+cell+responses+and+protective+immunity+in+mice+and+guinea+pigs&amp;rft.volume=34&amp;rft.issue=1&amp;rft.pages=101-9&amp;rft.date=2016-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.vaccine.2015.10.137&amp;rft_id=info%3Apmid%2F26571309&amp;rft.aulast=Odegard&amp;rft.aufirst=JM&amp;rft.au=Flynn%2C+PA&amp;rft.au=Campbell%2C+DJ&amp;rft.au=Robbins%2C+SH&amp;rft.au=Dong%2C+L&amp;rft.au=Wang%2C+K&amp;rft.au=Ter+Meulen%2C+J&amp;rft.au=Cohen%2C+JI&amp;rft.au=Koelle%2C+DM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-auto1-19\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-auto1_19-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-auto1_19-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.genvec.com/product-pipeline/gv2207-hsv-2-immunotherapeutic\">\"GV2207 \u2013 HSV-2 Immunotherapeutic&#160;:: GenVec, Inc. (GNVC)\"</a>. <i>www.genvec.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-08-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.genvec.com&amp;rft.atitle=GV2207+%E2%80%93+HSV-2+Immunotherapeutic+%3A%3A+GenVec%2C+Inc.+%28GNVC%29&amp;rft_id=http%3A%2F%2Fwww.genvec.com%2Fproduct-pipeline%2Fgv2207-hsv-2-immunotherapeutic&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nanobio.com/vaccine-pipeline/hsv-2-vaccine/\">\"Nanobio - HSV-2 Vaccine\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Nanobio+-+HSV-2+Vaccine&amp;rft_id=http%3A%2F%2Fwww.nanobio.com%2Fvaccine-pipeline%2Fhsv-2-vaccine%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Corporation, NanoBio. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.prnewswire.com/news-releases/nanobios-genital-herpes-vaccine-demonstrates-efficacy-in-guinea-pigs-as-both-a-prophylactic-and-a-therapeutic-vaccine-300147057.html\">\"NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NanoBio%27s+Genital+Herpes+Vaccine+Demonstrates+Efficacy+In+Guinea+Pigs+As+Both+A+Prophylactic+And+A+Therapeutic+Vaccine&amp;rft.aulast=Corporation&amp;rft.aufirst=NanoBio&amp;rft_id=http%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fnanobios-genital-herpes-vaccine-demonstrates-efficacy-in-guinea-pigs-as-both-a-prophylactic-and-a-therapeutic-vaccine-300147057.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.profectusbiosciences.com/pipeline/pbsvax.html#hsv-2\">\"PBS Vax\u2122 Therapeutic Vaccines\"</a>. <i>profectusbiosciences.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=profectusbiosciences.com&amp;rft.atitle=PBS+Vax%E2%84%A2+Therapeutic+Vaccines&amp;rft_id=http%3A%2F%2Fwww.profectusbiosciences.com%2Fpipeline%2Fpbsvax.html%23hsv-2&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.merckvaccines.com/Products/Zostavax/efficacy/\">\"Efficacy in Adults Aged 50 Years or Older\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-01-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Efficacy+in+Adults+Aged+50+Years+or+Older&amp;rft_id=https%3A%2F%2Fwww.merckvaccines.com%2FProducts%2FZostavax%2Fefficacy%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf\">\"VARIVAX\u00ae Varicella Virus Vaccine Live\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">30 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=VARIVAX%C2%AE+Varicella+Virus+Vaccine+Live&amp;rft_id=https%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvarivax%2Fvarivax_pi.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://au.gsk.com/media/216354/varilrix_cmi_au_007_approved.pdf\">\"VARILRIX\u00ae Live attenuated varicella vaccine\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">23 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=VARILRIX%C2%AE+Live+attenuated+varicella+vaccine&amp;rft_id=https%3A%2F%2Fau.gsk.com%2Fmedia%2F216354%2Fvarilrix_cmi_au_007_approved.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/wer/2014/wer8925.pdf\">\"Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-03</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Releve+epidemiologique+hebdomadaire+%2F+Section+d%27hygiene+du+Secretariat+de+la+Societe+des+Nations+%3D+Weekly+epidemiological+record+%2F+Health+Section+of+the+Secretariat+of+the+League+of+Nations&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fwer%2F2014%2Fwer8925.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3956\">\"Vaccine Detail GSK1437173A\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">31 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vaccine+Detail+GSK1437173A&amp;rft_id=http%3A%2F%2Fwww.violinet.org%2Fvaxquery%2Fvaccine_detail.php%3Fc_vaccine_id%3D3956&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nature.com-28\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-nature.com_28-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-nature.com_28-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sandgren KJ, Bertram K, Cunningham AL (July 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/cti/journal/v5/n7/full/cti201644a.html\">\"Understanding natural herpes simplex virus immunity to inform next-generation vaccine design\"</a>. <i>Clinical &amp; Translational Immunology</i>. <b>5</b> (7): e94. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/cti.2016.44\">10.1038/cti.2016.44</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27525067\">27525067</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+%26+Translational+Immunology&amp;rft.atitle=Understanding+natural+herpes+simplex+virus+immunity+to+inform+next-generation+vaccine+design&amp;rft.volume=5&amp;rft.issue=7&amp;rft.pages=e94&amp;rft.date=2016-07&amp;rft_id=info%3Adoi%2F10.1038%2Fcti.2016.44&amp;rft_id=info%3Apmid%2F27525067&amp;rft.aulast=Sandgren&amp;rft.aufirst=KJ&amp;rft.au=Bertram%2C+K&amp;rft.au=Cunningham%2C+AL&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fcti%2Fjournal%2Fv5%2Fn7%2Ffull%2Fcti201644a.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004336/human_med_002240.jsp&amp;mid=WC0b01ac058001d124\">\"Shingrix, herpes zoster vaccine (recombinant, adjuvanted)\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-02</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Shingrix%2C+herpes+zoster+vaccine+%28recombinant%2C+adjuvanted%29&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fmedicines%2Fhuman%2Fmedicines%2F004336%2Fhuman_med_002240.jsp%26mid%3DWC0b01ac058001d124&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Loyd_2017-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Loyd_2017_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Loyd, Linda (2017-06-21). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.philly.com/philly/business/glaxosmithkline-reports-positive-results-with-its-shingles-vaccine-20170622.html\">\"GlaxoSmithKline reports positive results with its shingles vaccine\"</a>. <i>Philly.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-09-26</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Philly.com&amp;rft.atitle=GlaxoSmithKline+reports+positive+results+with+its+shingles+vaccine&amp;rft.date=2017-06-21&amp;rft.aulast=Loyd&amp;rft.aufirst=Linda&amp;rft_id=http%3A%2F%2Fwww.philly.com%2Fphilly%2Fbusiness%2Fglaxosmithkline-reports-positive-results-with-its-shingles-vaccine-20170622.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Halford WP, P\u00fcschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B (March 2011). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3055896\">\"A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine\"</a>. <i>PLOS One</i>. <b>6</b> (3): e17748. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2011PLoSO...617748H\">2011PLoSO...617748H</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.pone.0017748\">10.1371/journal.pone.0017748</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3055896\">3055896</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21412438\">21412438</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+One&amp;rft.atitle=A+live-attenuated+HSV-2+ICP0+virus+elicits+10+to+100+times+greater+protection+against+genital+herpes+than+a+glycoprotein+D+subunit+vaccine&amp;rft.volume=6&amp;rft.issue=3&amp;rft.pages=e17748&amp;rft.date=2011-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3055896&amp;rft_id=info%3Apmid%2F21412438&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0017748&amp;rft_id=info%3Abibcode%2F2011PLoSO...617748H&amp;rft.aulast=Halford&amp;rft.aufirst=WP&amp;rft.au=P%C3%BCschel%2C+R&amp;rft.au=Gershburg%2C+E&amp;rft.au=Wilber%2C+A&amp;rft.au=Gershburg%2C+S&amp;rft.au=Rakowski%2C+B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3055896&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Halford WP, Geltz J, Gershburg E (2013). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0065523\">\"Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2\"</a>. <i>PLOS One</i>. <b>8</b> (6): e65523. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2013PLoSO...865523H\">2013PLoSO...865523H</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.pone.0065523\">10.1371/journal.pone.0065523</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3675040\">3675040</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23755244\">23755244</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+One&amp;rft.atitle=Pan-HSV-2+IgG+antibody+in+vaccinated+mice+and+guinea+pigs+correlates+with+protection+against+herpes+simplex+virus+2&amp;rft.volume=8&amp;rft.issue=6&amp;rft.pages=e65523&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3675040&amp;rft_id=info%3Apmid%2F23755244&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0065523&amp;rft_id=info%3Abibcode%2F2013PLoSO...865523H&amp;rft.aulast=Halford&amp;rft.aufirst=WP&amp;rft.au=Geltz%2C+J&amp;rft.au=Gershburg%2C+E&amp;rft_id=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0065523&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Halford WP, P\u00fcschel R, Rakowski B (August 2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012251\">\"Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine\"</a>. <i>PLOS One</i>. <b>5</b> (8): e12251. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2010PLoSO...512251H\">2010PLoSO...512251H</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.pone.0012251\">10.1371/journal.pone.0012251</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2923193\">2923193</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20808928\">20808928</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+One&amp;rft.atitle=Herpes+simplex+virus+2+ICP0+mutant+viruses+are+avirulent+and+immunogenic%3A+implications+for+a+genital+herpes+vaccine&amp;rft.volume=5&amp;rft.issue=8&amp;rft.pages=e12251&amp;rft.date=2010-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2923193&amp;rft_id=info%3Apmid%2F20808928&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0012251&amp;rft_id=info%3Abibcode%2F2010PLoSO...512251H&amp;rft.aulast=Halford&amp;rft.aufirst=WP&amp;rft.au=P%C3%BCschel%2C+R&amp;rft.au=Rakowski%2C+B&amp;rft_id=http%3A%2F%2Fjournals.plos.org%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0012251&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-34\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Olsen, Dean. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sj-r.com/news/20170703/herpes-vaccine-trials-to-continue-after-siu-med-school-scientists-death\">\"Herpes vaccine trials to continue after SIU med school scientist's death\"</a>. <i>The State Journal</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-01-04</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+State+Journal&amp;rft.atitle=Herpes+vaccine+trials+to+continue+after+SIU+med+school+scientist%27s+death&amp;rft.aulast=Olsen&amp;rft.aufirst=Dean&amp;rft_id=http%3A%2F%2Fwww.sj-r.com%2Fnews%2F20170703%2Fherpes-vaccine-trials-to-continue-after-siu-med-school-scientists-death&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Bloom_2018-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Bloom_2018_35-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Bloom, Josh (2018-02-08). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.acsh.org/news/2018/02/08/i-met-theravax-herpes-vaccine-patient-and-here-what-he-said-12543\">\"I Met With A Theravax Herpes Vaccine Patient And Here Is What He Said\"</a>. <i>acsh.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-08-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=acsh.org&amp;rft.atitle=I+Met+With+A+Theravax+Herpes+Vaccine+Patient+And+Here+Is+What+He+Said&amp;rft.date=2018-02-08&amp;rft.aulast=Bloom&amp;rft.aufirst=Josh&amp;rft_id=https%3A%2F%2Fwww.acsh.org%2Fnews%2F2018%2F02%2F08%2Fi-met-theravax-herpes-vaccine-patient-and-here-what-he-said-12543&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mundle ST, Hernandez H, Hamberger J, Catalan J, Zhou C, Stegalkina S, Tiffany A, Kleanthous H, Delagrave S, Anderson SF (2013). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3582571\">\"High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo\"</a>. <i>PLOS One</i>. <b>8</b> (2): e57224. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2013PLoSO...857224M\">2013PLoSO...857224M</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.pone.0057224\">10.1371/journal.pone.0057224</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3582571\">3582571</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23468943\">23468943</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+One&amp;rft.atitle=High-purity+preparation+of+HSV-2+vaccine+candidate+ACAM529+is+immunogenic+and+efficacious+in+vivo&amp;rft.volume=8&amp;rft.issue=2&amp;rft.pages=e57224&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3582571&amp;rft_id=info%3Apmid%2F23468943&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0057224&amp;rft_id=info%3Abibcode%2F2013PLoSO...857224M&amp;rft.aulast=Mundle&amp;rft.aufirst=ST&amp;rft.au=Hernandez%2C+H&amp;rft.au=Hamberger%2C+J&amp;rft.au=Catalan%2C+J&amp;rft.au=Zhou%2C+C&amp;rft.au=Stegalkina%2C+S&amp;rft.au=Tiffany%2C+A&amp;rft.au=Kleanthous%2C+H&amp;rft.au=Delagrave%2C+S&amp;rft.au=Anderson%2C+SF&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3582571&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://knipelab.med.harvard.edu/pdfs/2007van%20Lint%20et%20al.pdf\">\"Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>ScienceDirect</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">May 20,</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=ScienceDirect&amp;rft.atitle=Immunization+with+a+replication-defective+herpes+simplex+virus+2+mutant+reduces+herpes+simplex+virus+1+infection+and+prevents+ocular+disease&amp;rft_id=http%3A%2F%2Fknipelab.med.harvard.edu%2Fpdfs%2F2007van%2520Lint%2520et%2520al.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HSV11-8-13.aspx\">\"NIH Launches Trial of Investigational Genital Herpes Vaccine\"</a>. <i>NIAID</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 September</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NIAID&amp;rft.atitle=NIH+Launches+Trial+of+Investigational+Genital+Herpes+Vaccine&amp;rft_id=http%3A%2F%2Fwww.niaid.nih.gov%2Fnews%2Fnewsreleases%2F2013%2FPages%2FHSV11-8-13.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-39\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://knipelab.med.harvard.edu/pdfs/Hoshino_etal_2005_JV.pdf\">\"Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>JOURNAL OF VIROLOGY</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">May 20,</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=JOURNAL+OF+VIROLOGY&amp;rft.atitle=Comparative+Efficacy+and+Immunogenicity+of+Replication-Defective%2C+Recombinant+Glycoprotein%2C+and+DNA+Vaccines+for+Herpes+Simplex+Virus+2+Infections+in+Mice+and+Guinea+Pigs&amp;rft_id=http%3A%2F%2Fknipelab.med.harvard.edu%2Fpdfs%2FHoshino_etal_2005_JV.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://archives.focus.hms.harvard.edu/2008/030708/licensing.shtml\">\"FOCUS &#124; March 7, 2008 &#124; LICENSING: Herpes Vaccine Developed at HMS Licensed for Preclinical Trials\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FOCUS+%26%23124%3B+March+7%2C+2008+%26%23124%3B+LICENSING%3A+Herpes+Vaccine+Developed+at+HMS+Licensed+for+Preclinical+Trials&amp;rft_id=http%3A%2F%2Farchives.focus.hms.harvard.edu%2F2008%2F030708%2Flicensing.shtml&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ir.immunedesign.com/releasedetail.cfm?ReleaseID=876534\">\"Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 October</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Sanofi+Pasteur+and+Immune+Design+Enter+Broad+Collaboration+for+the+Development+of+a+Herpes+Simplex+Virus+Therapy&amp;rft_id=http%3A%2F%2Fir.immunedesign.com%2Freleasedetail.cfm%3FReleaseID%3D876534&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/show/NCT01915212\">\"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-04</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Study+of+the+Safety+of+a+Particular+Herpes+Vaccine+in+Adults+With+or+Without+Herpes+Infection&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01915212&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.hsvoutbreak.com/potential-cure-for-the-herpes-simplex-virus\">\"Potential Cure For Herpes Simplex Virus\"</a>. HSV Outbreak<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 August</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Potential+Cure+For+Herpes+Simplex+Virus&amp;rft.pub=HSV+Outbreak&amp;rft_id=http%3A%2F%2Fwww.hsvoutbreak.com%2Fpotential-cure-for-the-herpes-simplex-virus&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-44\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.couriermail.com.au/news/queensland/gardasil-inventor-professor-ian-frazers-new-genital-herpes-vaccine-proves-safe-in-passing-first-human-trials/story-fnihsrf2-1226817096262\">\"Gardasil inventor Professor Ian Frazer's new genital herpes vaccine proves safe in passing first human trials\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 February</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Gardasil+inventor+Professor+Ian+Frazer%27s+new+genital+herpes+vaccine+proves+safe+in+passing+first+human+trials&amp;rft_id=http%3A%2F%2Fwww.couriermail.com.au%2Fnews%2Fqueensland%2Fgardasil-inventor-professor-ian-frazers-new-genital-herpes-vaccine-proves-safe-in-passing-first-human-trials%2Fstory-fnihsrf2-1226817096262&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.proactiveinvestors.com.au/companies/news/57916/admedus-vaccine-for-herpes-has-success-moves-to-next-clinical-trial-57916.html\">\"Admedus vaccine for herpes has success; moves to next clinical trial\"</a>. Proactive Investors<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">3 October</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Admedus+vaccine+for+herpes+has+success%3B+moves+to+next+clinical+trial&amp;rft_id=http%3A%2F%2Fwww.proactiveinvestors.com.au%2Fcompanies%2Fnews%2F57916%2Fadmedus-vaccine-for-herpes-has-success-moves-to-next-clinical-trial-57916.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-46\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.proactiveinvestors.com.au/companies/news/56472/admedus-increases-interest-in-prof-ian-frazers-vaccines-56472.html\">\"Admedus increases interest in Prof Ian Frazer's vaccines\"</a>. Proactive Investors<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">3 September</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Admedus+increases+interest+in+Prof+Ian+Frazer%27s+vaccines&amp;rft.pub=Proactive+Investors&amp;rft_id=http%3A%2F%2Fwww.proactiveinvestors.com.au%2Fcompanies%2Fnews%2F56472%2Fadmedus-increases-interest-in-prof-ian-frazers-vaccines-56472.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-47\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-47\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.proactiveinvestors.com.au/companies/news/61686/admedus-has-high-hopes-for-herpes-vaccine-as-dosing-commences-61686.html\">\"Admedus has high hopes for Herpes vaccine as dosing commences - Proactiveinvestors (AU)\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Admedus+has+high+hopes+for+Herpes+vaccine+as+dosing+commences+-+Proactiveinvestors+%28AU%29&amp;rft_id=http%3A%2F%2Fwww.proactiveinvestors.com.au%2Fcompanies%2Fnews%2F61686%2Fadmedus-has-high-hopes-for-herpes-vaccine-as-dosing-commences-61686.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-48\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-48\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://clients2.weblink.com.au/news/pdf_2%5C01791053.pdf\">\"ADMEDUS ANNOUNCES POSITIVE UNBLINDED HSV-2 PHASE II INTERIM DATA\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Admedus</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Admedus&amp;rft.atitle=ADMEDUS+ANNOUNCES+POSITIVE+UNBLINDED+HSV-2+PHASE+II+INTERIM+DATA&amp;rft_id=http%3A%2F%2Fclients2.weblink.com.au%2Fnews%2Fpdf_2%255C01791053.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-49\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://elifesciences.org/content/4/e06054\">\"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease\"</a>. eLife Science<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 March</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Herpes+simplex+type+2+virus+deleted+in+glycoprotein+D+protects+against+vaginal%2C+skin+and+neural+disease&amp;rft.pub=eLife+Science&amp;rft_id=http%3A%2F%2Felifesciences.org%2Fcontent%2F4%2Fe06054&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-50\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-50\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.hhmi.org/news/radical-vaccine-design-effective-against-herpes-viruses\">\"Radical Vaccine Design Effective Against Herpes Virus\"</a>. HHMI.org<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 March</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Radical+Vaccine+Design+Effective+Against+Herpes+Virus&amp;rft.pub=HHMI.org&amp;rft_id=http%3A%2F%2Fwww.hhmi.org%2Fnews%2Fradical-vaccine-design-effective-against-herpes-viruses&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-51\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-51\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nanobio.com/GenitalHerpesProphylacticTherapeuticVaccine.html\">\"NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine\"</a>. NanoBio Corporation<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 October</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NanoBio%27s+Genital+Herpes+Vaccine+Demonstrates+Efficacy+In+Guinea+Pigs+As+Both+A+Prophylactic+And+A+Therapeutic+Vaccine&amp;rft.pub=NanoBio+Corporation&amp;rft_id=http%3A%2F%2Fwww.nanobio.com%2FGenitalHerpesProphylacticTherapeuticVaccine.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-52\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.profectusbiosciences.com/pipeline/pbsvax.html#hsv-2\">\"Pipeline for PBS Vax\u2122 Therapeutic Vaccines\"</a>. Profectus Biosciences<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pipeline+for+PBS+Vax%E2%84%A2+Therapeutic+Vaccines&amp;rft.pub=Profectus+Biosciences&amp;rft_id=http%3A%2F%2Fwww.profectusbiosciences.com%2Fpipeline%2Fpbsvax.html%23hsv-2&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-53\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-53\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.vaccinenation.org/2014/06/10/biomedical-research-models-inc-brm-awarded-3-0-million-nih-grant-advance-mucosal-hsv-2-vaccine-towards-clinical-trials/\">\"BioMedical Research Models Inc awarded Grant for Mucosal HSV-2 vaccine\"</a>. Vaccine Nation (Cameron Bisset)<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">13 June</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=BioMedical+Research+Models+Inc+awarded+Grant+for+Mucosal+HSV-2+vaccine&amp;rft.pub=Vaccine+Nation+%28Cameron+Bisset%29&amp;rft_id=http%3A%2F%2Fwww.vaccinenation.org%2F2014%2F06%2F10%2Fbiomedical-research-models-inc-brm-awarded-3-0-million-nih-grant-advance-mucosal-hsv-2-vaccine-towards-clinical-trials%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://projectreporter.nih.gov/project_info_description.cfm?aid=8713366&amp;icde=0\">\"Project Information - NIH RePORTER - NIH Research Portfolio Online Reporting Tools Expenditures and Results\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Project+Information+-+NIH+RePORTER+-+NIH+Research+Portfolio+Online+Reporting+Tools+Expenditures+and+Results&amp;rft_id=https%3A%2F%2Fprojectreporter.nih.gov%2Fproject_info_description.cfm%3Faid%3D8713366%26icde%3D0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-55\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-55\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.redbiotec.ch/product/hsv-2/\">http://www.redbiotec.ch/product/hsv-2/</a></span>\n</li>\n<li id=\"cite_note-56\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-56\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://news.feinberg.northwestern.edu/2017/12/herpes-virus-mutant-points-towards-new-vaccine-strategy/\">http://news.feinberg.northwestern.edu/2017/12/herpes-virus-mutant-points-towards-new-vaccine-strategy/</a></span>\n</li>\n<li id=\"cite_note-57\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-57\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/immunization/research/meetings_workshops/HSV_vaccineRD_Sept2014.pdf\">\"Status of Vaccine Research and Development of Vaccines for Herpes Simplex Virus\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">30 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Status+of+Vaccine+Research+and+Development+of+Vaccines+for+Herpes+Simplex+Virus&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fimmunization%2Fresearch%2Fmeetings_workshops%2FHSV_vaccineRD_Sept2014.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-58\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-58\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.niaid.nih.gov/news-events/genital-herpes-vaccine-moderately-protective-against-one-two-herpes-viruses\">\"QUESTIONS AND ANSWERS The Herpevac Trial for Women\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">30 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=QUESTIONS+AND+ANSWERS+The+Herpevac+Trial+for+Women&amp;rft_id=https%3A%2F%2Fwww.niaid.nih.gov%2Fnews-events%2Fgenital-herpes-vaccine-moderately-protective-against-one-two-herpes-viruses&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ReferenceA-59\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ReferenceA_59-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ReferenceA_59-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cohen J (October 2010). \"Immunology. Painful failure of promising genital herpes vaccine\". <i>Science</i>. <b>330</b> (6002): 304. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2010Sci...330..304C\">2010Sci...330..304C</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1126/science.330.6002.304\">10.1126/science.330.6002.304</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20947733\">20947733</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=Immunology.+Painful+failure+of+promising+genital+herpes+vaccine&amp;rft.volume=330&amp;rft.issue=6002&amp;rft.pages=304&amp;rft.date=2010-10&amp;rft_id=info%3Apmid%2F20947733&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.330.6002.304&amp;rft_id=info%3Abibcode%2F2010Sci...330..304C&amp;rft.aulast=Cohen&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-60\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-60\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.paxvax.com/about/news/paxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus\">\"PaxVax Signs R&amp;D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections\"</a>. <i>paxvax.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=paxvax.com&amp;rft.atitle=PaxVax+Signs+R%26D+Collaboration+with+UC+San+Diego+to+Develop+a+Vaccine+to+Prevent+Herpes+Simplex+Virus+Infections&amp;rft_id=http%3A%2F%2Fwww.paxvax.com%2Fabout%2Fnews%2Fpaxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-61\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-61\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.paxvax.com/about\">\"About\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=About&amp;rft_id=http%3A%2F%2Fwww.paxvax.com%2Fabout&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-paxvax.com-62\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-paxvax.com_62-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-paxvax.com_62-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.paxvax.com/the-paxvax-solution/product-pipeline\">\"The PaxVax Platform - Product Pipeline\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 September</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+PaxVax+Platform+-+Product+Pipeline&amp;rft_id=http%3A%2F%2Fwww.paxvax.com%2Fthe-paxvax-solution%2Fproduct-pipeline&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-63\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-63\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://jvi.asm.org/content/86/8/4586.full\">\"Live Attenuated Herpes Simplex Virus 2 Glycoprotein E Deletion Mutant as a Vaccine Candidate Defective in Neuronal Spread\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">20 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Live+Attenuated+Herpes+Simplex+Virus+2+Glycoprotein+E+Deletion+Mutant+as+a+Vaccine+Candidate+Defective+in+Neuronal+Spread&amp;rft_id=http%3A%2F%2Fjvi.asm.org%2Fcontent%2F86%2F8%2F4586.full&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Amgen_Pipeline-64\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Amgen_Pipeline_64-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Amgen_Pipeline_64-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.amgen.com/science/pipe.html\">\"Amgen Pipeline\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Amgen+Pipeline&amp;rft_id=http%3A%2F%2Fwww.amgen.com%2Fscience%2Fpipe.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-65\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-65\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170926075918/http://ir.genocea.com/releasedetail.cfm?ReleaseID=1041589\">\"Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines\"</a>. <i>Genocea</i>. 25 September 2017. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://ir.genocea.com/releasedetail.cfm?ReleaseID=1041589\">the original</a> on 2017-09-26.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Genocea&amp;rft.atitle=Genocea+Announces+Strategic+Shift+to+Immuno-oncology+and+the+Development+of+Neoantigen+Cancer+Vaccines&amp;rft.date=2017-09-25&amp;rft_id=http%3A%2F%2Fir.genocea.com%2Freleasedetail.cfm%3FReleaseID%3D1041589&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-66\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-66\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.aurx.com/herpes.htm\">\"AuRx, Inc\"</a>. AuRx<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=AuRx%2C+Inc&amp;rft.pub=AuRx&amp;rft_id=http%3A%2F%2Fwww.aurx.com%2Fherpes.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-67\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-67\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.aurx.com/herpes2.htm\">\"AuRx, Inc\"</a>. AuRx<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=AuRx%2C+Inc&amp;rft.pub=AuRx&amp;rft_id=http%3A%2F%2Fwww.aurx.com%2Fherpes2.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-68\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">McAllister SC, Schleiss MR (November 2014). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4385587\">\"Prospects and perspectives for development of a vaccine against herpes simplex virus infections\"</a>. <i>Expert Review of Vaccines</i>. <b>13</b> (11): 1349\u201360. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1586/14760584.2014.932694\">10.1586/14760584.2014.932694</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4385587\">4385587</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25077372\">25077372</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Review+of+Vaccines&amp;rft.atitle=Prospects+and+perspectives+for+development+of+a+vaccine+against+herpes+simplex+virus+infections&amp;rft.volume=13&amp;rft.issue=11&amp;rft.pages=1349-60&amp;rft.date=2014-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4385587&amp;rft_id=info%3Apmid%2F25077372&amp;rft_id=info%3Adoi%2F10.1586%2F14760584.2014.932694&amp;rft.aulast=McAllister&amp;rft.aufirst=SC&amp;rft.au=Schleiss%2C+MR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4385587&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-69\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_69-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_69-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.mymetics.com/vaccine-pipeline/herpes-simplex/\">\"Mymetics HSV Vaccine Candidate\"</a>. Mymetics<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 April</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mymetics+HSV+Vaccine+Candidate&amp;rft.pub=Mymetics&amp;rft_id=http%3A%2F%2Fwww.mymetics.com%2Fvaccine-pipeline%2Fherpes-simplex%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-70\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-70\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/show/NCT01687595?term=HerpV&amp;rank=1\">\"Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">31 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Biological+Efficacy+Study+of+HerpV+Vaccine+With+QS-21+to+Treat+Subjects+With+Recurrent+Genital+Herpes&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01687595%3Fterm%3DHerpV%26rank%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-71\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-71\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.vical.com/products/HSV-2-vaccine/default.aspx\">\"Vical HSV-2 Therapeutic Vaccine VCL-HB01\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vical+HSV-2+Therapeutic+Vaccine+VCL-HB01&amp;rft_id=http%3A%2F%2Fwww.vical.com%2Fproducts%2FHSV-2-vaccine%2Fdefault.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-vical.com-72\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-vical.com_72-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-vical.com_72-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.vical.com/investors/news-releases/News-Release-Details/2018/Vical-Reports-Phase-2-Trial-of-HSV-2-Therapeutic-Vaccine-Did-Not-Meet-Primary-Endpoint/default.aspx\">\"Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint\"</a>. <i>Vical.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">16 June</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Vical.com&amp;rft.atitle=Vical+Reports+Phase+2+Trial+of+HSV-2+Therapeutic+Vaccine+Did+Not+Meet+Primary+Endpoint&amp;rft_id=http%3A%2F%2Fwww.vical.com%2Finvestors%2Fnews-releases%2FNews-Release-Details%2F2018%2FVical-Reports-Phase-2-Trial-of-HSV-2-Therapeutic-Vaccine-Did-Not-Meet-Primary-Endpoint%2Fdefault.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-autogenerated1-73\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated1_73-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated1_73-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20071020035054/http://www.niaid.nih.gov/dmid/stds/herpevac/studyover_faqs.htm\">\"Herpevac Trial for Women\"</a>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.niaid.nih.gov/dmid/stds/herpevac/studyover_faqs.htm\">the original</a> on 2007-10-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2008-03-04</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Herpevac+Trial+for+Women&amp;rft_id=http%3A%2F%2Fwww.niaid.nih.gov%2Fdmid%2Fstds%2Fherpevac%2Fstudyover_faqs.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-74\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-74\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://paxvax.com/about/news/paxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus\">\"PaxVax Signs R&amp;D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections - PaxVax - Socially Responsible Vaccines\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=PaxVax+Signs+R%26D+Collaboration+with+UC+San+Diego+to+Develop+a+Vaccine+to+Prevent+Herpes+Simplex+Virus+Infections+-+PaxVax+-+Socially+Responsible+Vaccines&amp;rft_id=http%3A%2F%2Fpaxvax.com%2Fabout%2Fnews%2Fpaxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-75\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-75\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.news-medical.net/news/20100304/BioVex-commences-dosing-in-Phase-1-study-of-ImmunoVEX-live-attenuated-genital-herpes-vaccine.aspx\">\"BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine\"</a>. 5 March 2010<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=BioVex+commences+dosing+in+Phase+1+study+of+ImmunoVEX+live+attenuated+genital+herpes+vaccine&amp;rft.date=2010-03-05&amp;rft_id=http%3A%2F%2Fwww.news-medical.net%2Fnews%2F20100304%2FBioVex-commences-dosing-in-Phase-1-study-of-ImmunoVEX-live-attenuated-genital-herpes-vaccine.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-76\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-76\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.boston.com/business/healthcare/articles/2011/03/04/amgen_completes_acquisition_of_biovex_group/\">\"Amgen completes acquisition of BioVex Group\"</a>. 4 March 2011<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>  &#8211; via The Boston Globe.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Amgen+completes+acquisition+of+BioVex+Group&amp;rft.date=2011-03-04&amp;rft_id=http%3A%2F%2Fwww.boston.com%2Fbusiness%2Fhealthcare%2Farticles%2F2011%2F03%2F04%2Famgen_completes_acquisition_of_biovex_group%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-77\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-77\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.aurx.com/pressrelease013.htm\">\"AuRx, Inc\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=AuRx%2C+Inc&amp;rft_id=http%3A%2F%2Fwww.aurx.com%2Fpressrelease013.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.businesswire.com/news/home/20140626005211/en/Agenus-Vaccine-Shows-Significant-Reduction-Viral-Burden\">\"Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation\"</a>. Business Wire<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 September</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Agenus+Vaccine+Shows+Significant+Reduction+in+Viral+Burden+after+HerpV+Generated+Immune+Activation&amp;rft.pub=Business+Wire&amp;rft_id=http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20140626005211%2Fen%2FAgenus-Vaccine-Shows-Significant-Reduction-Viral-Burden&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-79\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-79\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://justherpes.com/herpes-news/herpes-news-2014/\">\"Herpes News: Early 2014 Roundup - Just Herpes\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Herpes+News%3A+Early+2014+Roundup+-+Just+Herpes&amp;rft_id=http%3A%2F%2Fjustherpes.com%2Fherpes-news%2Fherpes-news-2014%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-80\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-80\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://agenusbio.com/pipeline/\">\"Pipeline - Agenus\"</a>. <i>agenusbio.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 September</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=agenusbio.com&amp;rft.atitle=Pipeline+-+Agenus&amp;rft_id=http%3A%2F%2Fagenusbio.com%2Fpipeline%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-81\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-81\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.genocea.com/assets/vanWagoner_GEN003_IDWeek2015_poster_presented_09Oct2015.pdf\">\"Genocea Corporate Overview\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Genocea<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Genocea+Corporate+Overview&amp;rft.pub=Genocea&amp;rft_id=http%3A%2F%2Fwww.genocea.com%2Fassets%2FvanWagoner_GEN003_IDWeek2015_poster_presented_09Oct2015.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-82\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ir.genocea.com/releasedetail.cfm?ReleaseID=1041589\">\"Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines\"</a>. <i>genocea.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 September</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=genocea.com&amp;rft.atitle=Genocea+Announces+Strategic+Shift+to+Immuno-oncology+and+the+Development+of+Neoantigen+Cancer+Vaccines&amp;rft_id=http%3A%2F%2Fir.genocea.com%2Freleasedetail.cfm%3FReleaseID%3D1041589&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-83\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-83\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.streetinsider.com/Corporate+News/Vical+%28VICL%29+Genital+Herpes+Vaccine+Phase+12+Missed+Primary+Endpoint/10669728.html\">\"Vical (VICL) Genital Herpes Vaccine Phase 1/2 Missed Primary Endpoint\"</a>. StreetInsider.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 June</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vical+%28VICL%29+Genital+Herpes+Vaccine+Phase+1%2F2+Missed+Primary+Endpoint&amp;rft.pub=StreetInsider.com&amp;rft_id=http%3A%2F%2Fwww.streetinsider.com%2FCorporate%2BNews%2FVical%2B%2528VICL%2529%2BGenital%2BHerpes%2BVaccine%2BPhase%2B12%2BMissed%2BPrimary%2BEndpoint%2F10669728.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-84\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-84\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fiercebiotech.com/press-releases/vical-reports-top-line-results-phase-12-trial-therapeutic-genital-herpes-va\">\"Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine\"</a>. FierceMarkets. 22 June 2015<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">23 June</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vical+Reports+Top-Line+Results+From+Phase+1%2F2+Trial+of+Therapeutic+Genital+Herpes+Vaccine&amp;rft.date=2015-06-22&amp;rft_id=http%3A%2F%2Fwww.fiercebiotech.com%2Fpress-releases%2Fvical-reports-top-line-results-phase-12-trial-therapeutic-genital-herpes-va&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-85\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-85\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://globenewswire.com/news-release/2016/06/20/849939/0/en/Vical-s-Phase-1-2-Trial-Data-Presented-at-ASM-2016-Shows-Bivalent-Vaccine-Imparts-Reduction-in-Genital-Herpes-Lesions-Durable-to-9-Months.html\">\"Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months\"</a>. <i>Globe Newswire</i>. 2018-06-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 June</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Globe+Newswire&amp;rft.atitle=Vical%E2%80%99s+Phase+1%2F2+Trial+Data+Presented+at+ASM+2016+Shows+Bivalent+Vaccine+Imparts+Reduction+in+Genital+Herpes+Lesions+Durable+to+9+Months&amp;rft.date=2018-06-20&amp;rft_id=https%3A%2F%2Fglobenewswire.com%2Fnews-release%2F2016%2F06%2F20%2F849939%2F0%2Fen%2FVical-s-Phase-1-2-Trial-Data-Presented-at-ASM-2016-Shows-Bivalent-Vaccine-Imparts-Reduction-in-Genital-Herpes-Lesions-Durable-to-9-Months.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-86\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-86\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kennedy EM, Cullen BR (January 2017). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.annualreviews.org/doi/10.1146/annurev-med-051215-031129\">\"Gene Editing: A New Tool for Viral Disease\"</a>. <i>Annual Review of Medicine</i>. <b>68</b> (1): 401\u2013411. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1146/annurev-med-051215-031129\">10.1146/annurev-med-051215-031129</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27576009\">27576009</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annual+Review+of+Medicine&amp;rft.atitle=Gene+Editing%3A+A+New+Tool+for+Viral+Disease&amp;rft.volume=68&amp;rft.issue=1&amp;rft.pages=401-411&amp;rft.date=2017-01&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev-med-051215-031129&amp;rft_id=info%3Apmid%2F27576009&amp;rft.aulast=Kennedy&amp;rft.aufirst=EM&amp;rft.au=Cullen%2C+BR&amp;rft_id=http%3A%2F%2Fwww.annualreviews.org%2Fdoi%2F10.1146%2Fannurev-med-051215-031129&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-87\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-87\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Aubert M, Madden EA, Loprieno M, DeSilva Feelixge HS, Stensland L, Huang ML, Greninger AL, Roychoudhury P, Niyonzima N, Nguyen T, Magaret A, Galleto R, Stone D, Jerome KR (September 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://insight.jci.org/articles/view/88468\">\"In vivo disruption of latent HSV by designer endonuclease therapy\"</a>. <i>JCI Insight</i>. <b>1</b> (14). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1172/jci.insight.88468\">10.1172/jci.insight.88468</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5026126\">5026126</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27642635\">27642635</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JCI+Insight&amp;rft.atitle=In+vivo+disruption+of+latent+HSV+by+designer+endonuclease+therapy&amp;rft.volume=1&amp;rft.issue=14&amp;rft.date=2016-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5026126&amp;rft_id=info%3Apmid%2F27642635&amp;rft_id=info%3Adoi%2F10.1172%2Fjci.insight.88468&amp;rft.aulast=Aubert&amp;rft.aufirst=M&amp;rft.au=Madden%2C+EA&amp;rft.au=Loprieno%2C+M&amp;rft.au=DeSilva+Feelixge%2C+HS&amp;rft.au=Stensland%2C+L&amp;rft.au=Huang%2C+ML&amp;rft.au=Greninger%2C+AL&amp;rft.au=Roychoudhury%2C+P&amp;rft.au=Niyonzima%2C+N&amp;rft.au=Nguyen%2C+T&amp;rft.au=Magaret%2C+A&amp;rft.au=Galleto%2C+R&amp;rft.au=Stone%2C+D&amp;rft.au=Jerome%2C+KR&amp;rft_id=https%3A%2F%2Finsight.jci.org%2Farticles%2Fview%2F88468&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-88\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-88\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Engel, Mary (8 September 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fredhutch.org/en/news/center-news/2016/09/can-gene-editing-cure-herpes.html\">\"Can gene editing cure herpes?\"</a>. Fred Hutch News Service<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">7 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Can+gene+editing+cure+herpes%3F&amp;rft.pub=Fred+Hutch+News+Service&amp;rft.date=2016-09-08&amp;rft.aulast=Engel&amp;rft.aufirst=Mary&amp;rft_id=http%3A%2F%2Fwww.fredhutch.org%2Fen%2Fnews%2Fcenter-news%2F2016%2F09%2Fcan-gene-editing-cure-herpes.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-89\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-89\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kennedy EM, Cullen BR (May 2015). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencedirect.com/science/article/pii/S0042682215000707\">\"Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment\"</a>. <i>Virology</i>. 479-480: 213\u201320. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.virol.2015.02.024\">10.1016/j.virol.2015.02.024</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4424069\">4424069</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25759096\">25759096</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Virology&amp;rft.atitle=Bacterial+CRISPR%2FCas+DNA+endonucleases%3A+A+revolutionary+technology+that+could+dramatically+impact+viral+research+and+treatment&amp;rft.volume=479-480&amp;rft.pages=213-20&amp;rft.date=2015-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4424069&amp;rft_id=info%3Apmid%2F25759096&amp;rft_id=info%3Adoi%2F10.1016%2Fj.virol.2015.02.024&amp;rft.aulast=Kennedy&amp;rft.aufirst=EM&amp;rft.au=Cullen%2C+BR&amp;rft_id=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0042682215000707&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-90\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-90\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Roehm PC, Shekarabi M, Wollebo HS, Bellizzi A, He L, Salkind J, Khalili K (April 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/articles/srep23146\">\"Inhibition of HSV-1 Replication by Gene Editing Strategy\"</a>. <i>Scientific Reports</i>. <b>6</b>: 23146. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2016NatSR...623146R\">2016NatSR...623146R</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/srep23146\">10.1038/srep23146</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4827394\">4827394</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27064617\">27064617</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Scientific+Reports&amp;rft.atitle=Inhibition+of+HSV-1+Replication+by+Gene+Editing+Strategy&amp;rft.volume=6&amp;rft.pages=23146&amp;rft.date=2016-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4827394&amp;rft_id=info%3Apmid%2F27064617&amp;rft_id=info%3Adoi%2F10.1038%2Fsrep23146&amp;rft_id=info%3Abibcode%2F2016NatSR...623146R&amp;rft.aulast=Roehm&amp;rft.aufirst=PC&amp;rft.au=Shekarabi%2C+M&amp;rft.au=Wollebo%2C+HS&amp;rft.au=Bellizzi%2C+A&amp;rft.au=He%2C+L&amp;rft.au=Salkind%2C+J&amp;rft.au=Khalili%2C+K&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Farticles%2Fsrep23146&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-91\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-91\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Gordon, Lila. <a rel=\"nofollow\" class=\"external text\" href=\"http://temple-news.com/news/researchers-aim-to-find-cure-for-herpes/\">\"Researchers aim to find cure for herpes\"</a>. <i>The Temple News</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=The+Temple+News&amp;rft.atitle=Researchers+aim+to+find+cure+for+herpes&amp;rft.aulast=Gordon&amp;rft.aufirst=Lila&amp;rft_id=http%3A%2F%2Ftemple-news.com%2Fnews%2Fresearchers-aim-to-find-cure-for-herpes%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-92\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-92\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.excisionbio.com/pipeline\">\"Therapeutic and Vaccine Pipeline\"</a>. <i>Excision BioTherapeutics - Gene Editing Therapeutics</i>. Excision BioTherapeutics<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Excision+BioTherapeutics+-+Gene+Editing+Therapeutics&amp;rft.atitle=Therapeutic+and+Vaccine+Pipeline&amp;rft_id=http%3A%2F%2Fwww.excisionbio.com%2Fpipeline&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-93\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-93\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">van Diemen FR, Kruse EM, Hooykaas MJ, Bruggeling CE, Sch\u00fcrch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJ, Lebbink RJ (June 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005701\">\"CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections\"</a>. <i>PLoS Pathogens</i>. <b>12</b> (6): e1005701. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.ppat.1005701\">10.1371/journal.ppat.1005701</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4928872\">4928872</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27362483\">27362483</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS+Pathogens&amp;rft.atitle=CRISPR%2FCas9-Mediated+Genome+Editing+of+Herpesviruses+Limits+Productive+and+Latent+Infections&amp;rft.volume=12&amp;rft.issue=6&amp;rft.pages=e1005701&amp;rft.date=2016-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4928872&amp;rft_id=info%3Apmid%2F27362483&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.ppat.1005701&amp;rft.aulast=van+Diemen&amp;rft.aufirst=FR&amp;rft.au=Kruse%2C+EM&amp;rft.au=Hooykaas%2C+MJ&amp;rft.au=Bruggeling%2C+CE&amp;rft.au=Sch%C3%BCrch%2C+AC&amp;rft.au=van+Ham%2C+PM&amp;rft.au=Imhof%2C+SM&amp;rft.au=Nijhuis%2C+M&amp;rft.au=Wiertz%2C+EJ&amp;rft.au=Lebbink%2C+RJ&amp;rft_id=http%3A%2F%2Fjournals.plos.org%2Fplospathogens%2Farticle%3Fid%3D10.1371%2Fjournal.ppat.1005701&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-94\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-94\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Kassabian, Sara (4 August 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://blogs.plos.org/speakingofmedicine/2016/08/04/crispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation/\">\"CRISPR Puts Up a Fight Against Persistent Herpesviruses: A Short Animation\"</a>. <i>PLOS BLOGS</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 January</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=PLOS+BLOGS&amp;rft.atitle=CRISPR+Puts+Up+a+Fight+Against+Persistent+Herpesviruses%3A+A+Short+Animation&amp;rft.date=2016-08-04&amp;rft.aulast=Kassabian&amp;rft.aufirst=Sara&amp;rft_id=http%3A%2F%2Fblogs.plos.org%2Fspeakingofmedicine%2F2016%2F08%2F04%2Fcrispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-95\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-95\">^</a></b></span> <span class=\"reference-text\">Helicase\u2013primase inhibitors as the potential next generation of highly active drugs against herpes simplex viruses</span>\n</li>\n<li id=\"cite_note-96\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-96\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.aicuris.com/29/Research-Development/R-D-Pipeline.htm\">\"AiCuris - R&amp;D Pipeline\"</a>. <i>www.aicuris.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-09-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.aicuris.com&amp;rft.atitle=AiCuris+-+R%26D+Pipeline&amp;rft_id=http%3A%2F%2Fwww.aicuris.com%2F29%2FResearch-Development%2FR-D-Pipeline.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-97\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-97\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H (August 2011). \"Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes\". <i>Molecules</i>. <b>16</b> (9): 7210\u201323. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3390/molecules16097210\">10.3390/molecules16097210</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21869749\">21869749</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecules&amp;rft.atitle=Effect+of+ASP2151%2C+a+herpesvirus+helicase-primase+inhibitor%2C+in+a+guinea+pig+model+of+genital+herpes&amp;rft.volume=16&amp;rft.issue=9&amp;rft.pages=7210-23&amp;rft.date=2011-08&amp;rft_id=info%3Adoi%2F10.3390%2Fmolecules16097210&amp;rft_id=info%3Apmid%2F21869749&amp;rft.aulast=Katsumata&amp;rft.aufirst=K&amp;rft.au=Chono%2C+K&amp;rft.au=Sudo%2C+K&amp;rft.au=Shimizu%2C+Y&amp;rft.au=Kontani%2C+T&amp;rft.au=Suzuki%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-98\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-98\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Molecular Therapy (2006-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/mt/journal/v13/n1s/abs/mt2006942a.html\">\"Molecular Therapy \u2013 Abstract of article: 801. RNA Gene Therapy Targeting Herpes Simplex Virus\"</a>. Nature.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2011-04-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Molecular+Therapy+%E2%80%93+Abstract+of+article%3A+801.+RNA+Gene+Therapy+Targeting+Herpes+Simplex+Virus&amp;rft.pub=Nature.com&amp;rft.date=2006-05-01&amp;rft.au=Molecular+Therapy&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fmt%2Fjournal%2Fv13%2Fn1s%2Fabs%2Fmt2006942a.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-99\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-99\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20100613031337/http://news.ufl.edu/2009/02/03/herpes-2/\">\"University of Florida News \u2013Potential new herpes therapy studied\"</a>. News.ufl.edu. 2009-02-03. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://news.ufl.edu/2009/02/03/herpes-2/\">the original</a> on 2010-06-13<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2011-04-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=University+of+Florida+News+%E2%80%93Potential+new+herpes+therapy+studied&amp;rft.pub=News.ufl.edu&amp;rft.date=2009-02-03&amp;rft_id=http%3A%2F%2Fnews.ufl.edu%2F2009%2F02%2F03%2Fherpes-2%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-100\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-100\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Kassabian, Sara. <a rel=\"nofollow\" class=\"external text\" href=\"http://blogs.plos.org/speakingofmedicine/2016/08/04/crispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation/\">\"CRISPR Puts Up a Fight Against Persistent Herpesviruses: A Short Animation\"</a>. <i>Speaking of Medicine - PLOS Community Blog</i>. PLOS.org<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Speaking+of+Medicine+-+PLOS+Community+Blog&amp;rft.atitle=CRISPR+Puts+Up+a+Fight+Against+Persistent+Herpesviruses%3A+A+Short+Animation&amp;rft.aulast=Kassabian&amp;rft.aufirst=Sara&amp;rft_id=http%3A%2F%2Fblogs.plos.org%2Fspeakingofmedicine%2F2016%2F08%2F04%2Fcrispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-101\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-101\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">van Diemen, FR;  et al. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.youtube.com/watch?v=lQaWh8VLkiU&amp;feature=youtu.be\">\"Using CRISPR to combat viral infections: a new way to treat herpes?\"</a>. <i>PLOS Media YouTube Channel</i>. PLOS.org<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=PLOS+Media+YouTube+Channel&amp;rft.atitle=Using+CRISPR+to+combat+viral+infections%3A+a+new+way+to+treat+herpes%3F&amp;rft.aulast=van+Diemen&amp;rft.aufirst=FR&amp;rft_id=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DlQaWh8VLkiU%26feature%3Dyoutu.be&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-102\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-102\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Fox, Maggie (2008-07-02). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.reuters.com/article/idUSN0229815620080702?pageNumber=2&amp;virtualBrandChannel=0\">\"New approach offers chance to finally kill herpes\"</a>. Reuters<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2011-04-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=New+approach+offers+chance+to+finally+kill+herpes&amp;rft.date=2008-07-02&amp;rft.aulast=Fox&amp;rft.aufirst=Maggie&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2FidUSN0229815620080702%3FpageNumber%3D2%26virtualBrandChannel%3D0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-103\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-103\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Kingsbury, Kathleen (2008-07-02). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.time.com/time/health/article/0,8599,1819739,00.html\">\"A Cure for Cold Sores?\"</a>. <i>Time</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-05-04</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Time&amp;rft.atitle=A+Cure+for+Cold+Sores%3F&amp;rft.date=2008-07-02&amp;rft.aulast=Kingsbury&amp;rft.aufirst=Kathleen&amp;rft_id=http%3A%2F%2Fwww.time.com%2Ftime%2Fhealth%2Farticle%2F0%2C8599%2C1819739%2C00.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Martin-104\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Martin_104-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Martin_104-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, Hajitou A (August 2009). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2871293\">\"A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer\"</a>. <i>Molecular Cancer Therapeutics</i>. <b>8</b> (8): 2383\u201391. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1158/1535-7163.MCT-09-0110\">10.1158/1535-7163.MCT-09-0110</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2871293\">2871293</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19671758\">19671758</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Cancer+Therapeutics&amp;rft.atitle=A+heterotypic+bystander+effect+for+tumor+cell+killing+after+adeno-associated+virus%2Fphage-mediated%2C+vascular-targeted+suicide+gene+transfer&amp;rft.volume=8&amp;rft.issue=8&amp;rft.pages=2383-91&amp;rft.date=2009-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2871293&amp;rft_id=info%3Apmid%2F19671758&amp;rft_id=info%3Adoi%2F10.1158%2F1535-7163.MCT-09-0110&amp;rft.aulast=Trepel&amp;rft.aufirst=M&amp;rft.au=Stoneham%2C+CA&amp;rft.au=Eleftherohorinou%2C+H&amp;rft.au=Mazarakis%2C+ND&amp;rft.au=Pasqualini%2C+R&amp;rft.au=Arap%2C+W&amp;rft.au=Hajitou%2C+A&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2871293&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Mesnil-105\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Mesnil_105-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Mesnil_105-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Mesnil_105-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (March 1996). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC39867\">\"Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins\"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>93</b> (5): 1831\u20135. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/1996PNAS...93.1831M\">1996PNAS...93.1831M</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1073/pnas.93.5.1831\">10.1073/pnas.93.5.1831</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC39867\">39867</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/8700844\">8700844</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;rft.atitle=Bystander+killing+of+cancer+cells+by+herpes+simplex+virus+thymidine+kinase+gene+is+mediated+by+connexins&amp;rft.volume=93&amp;rft.issue=5&amp;rft.pages=1831-5&amp;rft.date=1996-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC39867&amp;rft_id=info%3Apmid%2F8700844&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.93.5.1831&amp;rft_id=info%3Abibcode%2F1996PNAS...93.1831M&amp;rft.aulast=Mesnil&amp;rft.aufirst=M&amp;rft.au=Piccoli%2C+C&amp;rft.au=Tiraby%2C+G&amp;rft.au=Willecke%2C+K&amp;rft.au=Yamasaki%2C+H&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC39867&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Stringer-106\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Stringer_106-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Stringer JR, Holland LE, Swanstrom RI, Pivo K, Wagner EK (March 1977). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC515626\">\"Quantitation of herpes simplex virus type 1 RNA in infected HeLa cells\"</a>. <i>Journal of Virology</i>. <b>21</b> (3): 889\u2013901. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC515626\">515626</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/191652\">191652</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Virology&amp;rft.atitle=Quantitation+of+herpes+simplex+virus+type+1+RNA+in+infected+HeLa+cells&amp;rft.volume=21&amp;rft.issue=3&amp;rft.pages=889-901&amp;rft.date=1977-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC515626&amp;rft_id=info%3Apmid%2F191652&amp;rft.aulast=Stringer&amp;rft.aufirst=JR&amp;rft.au=Holland%2C+LE&amp;rft.au=Swanstrom%2C+RI&amp;rft.au=Pivo%2C+K&amp;rft.au=Wagner%2C+EK&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC515626&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Jovanovic-107\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Jovanovic_107-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Jovanovic M, Hengartner MO (October 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/onc/journal/v25/n46/full/1209912a.html\">\"miRNAs and apoptosis: RNAs to die for\"</a>. <i>Oncogene</i>. <b>25</b> (46): 6176\u201387. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/sj.onc.1209912\">10.1038/sj.onc.1209912</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17028597\">17028597</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncogene&amp;rft.atitle=miRNAs+and+apoptosis%3A+RNAs+to+die+for&amp;rft.volume=25&amp;rft.issue=46&amp;rft.pages=6176-87&amp;rft.date=2006-10&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.onc.1209912&amp;rft_id=info%3Apmid%2F17028597&amp;rft.aulast=Jovanovic&amp;rft.aufirst=M&amp;rft.au=Hengartner%2C+MO&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fonc%2Fjournal%2Fv25%2Fn46%2Ffull%2F1209912a.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHerpes+simplex+research\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw2226\nCached time: 20180918140529\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.768 seconds\nReal time usage: 0.803 seconds\nPreprocessor visited node count: 3860/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 186631/2097152 bytes\nTemplate argument size: 466/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 137684/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.426/10.000 seconds\nLua memory usage: 3.44 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  671.231      1 -total\n 86.29%  579.233      1 Template:Reflist\n 41.84%  280.829     74 Template:Cite_web\n 23.69%  158.992     24 Template:Cite_journal\n  4.64%   31.113      1 Template:As_of\n  4.03%   27.038      1 Template:DMCA\n  3.59%   24.104      1 Template:Dated_maintenance_category\n  3.43%   23.020      6 Template:Cite_news\n  2.98%   19.973      1 Template:FULLROOTPAGENAME\n  2.60%   17.470      1 Template:Ns_has_subpages\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:35349626-0!canonical and timestamp 20180918140528 and revision id 856675445\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_containing_potentially_dated_statements_from_2016"},{"sortkey":"","hidden":"","*":"All_articles_containing_potentially_dated_statements"},{"sortkey":"","*":"Herpes"},{"sortkey":"","*":"Herpes_simplex_virus-associated_diseases"},{"sortkey":"","*":"Medical_research"}],"links":[{"ns":14,"exists":"","*":"Category:Articles containing potentially dated statements from 2016"},{"ns":0,"exists":"","*":"AS04"},{"ns":0,"exists":"","*":"Aciclovir"},{"ns":0,"exists":"","*":"Agenus"},{"ns":0,"exists":"","*":"Albert Einstein College of Medicine"},{"ns":0,"exists":"","*":"Alphaherpesvirinae"},{"ns":0,"exists":"","*":"Amenamevir"},{"ns":0,"exists":"","*":"American Society for Microbiology"},{"ns":0,"exists":"","*":"Amgen"},{"ns":0,"exists":"","*":"Antagomir"},{"ns":0,"exists":"","*":"Antibody"},{"ns":0,"exists":"","*":"Apoptosis"},{"ns":0,"exists":"","*":"Bibcode"},{"ns":0,"exists":"","*":"CRISPR"},{"ns":0,"exists":"","*":"CRISPR-Cas9"},{"ns":0,"exists":"","*":"Chickenpox"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Connexin"},{"ns":0,"exists":"","*":"Cytomegalovirus"},{"ns":0,"exists":"","*":"David M. Knipe"},{"ns":0,"exists":"","*":"Diffusion"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Duke University"},{"ns":0,"exists":"","*":"ETH Zurich"},{"ns":0,"exists":"","*":"Editas Medicine"},{"ns":0,"exists":"","*":"Endonuclease"},{"ns":0,"exists":"","*":"Epstein-Barr"},{"ns":0,"exists":"","*":"Epstein-Barr virus"},{"ns":0,"exists":"","*":"Famciclovir"},{"ns":0,"exists":"","*":"Fred Hutchinson Cancer Research Center"},{"ns":0,"exists":"","*":"GD2"},{"ns":0,"exists":"","*":"Ganglia"},{"ns":0,"exists":"","*":"Gap junctions"},{"ns":0,"exists":"","*":"Genome editing"},{"ns":0,"exists":"","*":"GlaxoSmithKline"},{"ns":0,"exists":"","*":"Hammerhead ribozyme"},{"ns":0,"exists":"","*":"Harvard Medical School"},{"ns":0,"exists":"","*":"HeLa cells"},{"ns":0,"exists":"","*":"Helicase-primase complex"},{"ns":0,"exists":"","*":"Herpes Simplex Keratitis"},{"ns":0,"exists":"","*":"Herpes simplex"},{"ns":0,"exists":"","*":"Herpes simplex virus"},{"ns":0,"exists":"","*":"Herpes simplex viruses"},{"ns":0,"exists":"","*":"Herpevac"},{"ns":0,"exists":"","*":"Human cytomegalovirus"},{"ns":0,"exists":"","*":"Ian Frazer"},{"ns":0,"exists":"","*":"Malignant"},{"ns":0,"exists":"","*":"Merck & Co."},{"ns":0,"exists":"","*":"MiRNAs"},{"ns":0,"exists":"","*":"Mononucleosis"},{"ns":0,"exists":"","*":"National Institutes of Health"},{"ns":0,"exists":"","*":"Nucleoside"},{"ns":0,"exists":"","*":"PaxVax"},{"ns":0,"exists":"","*":"Perelman School of Medicine at the University of Pennsylvania"},{"ns":0,"exists":"","*":"Phases of clinical research"},{"ns":0,"exists":"","*":"Phosphorylation"},{"ns":0,"exists":"","*":"Plasmid"},{"ns":0,"exists":"","*":"Pritelivir"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"QS21"},{"ns":0,"exists":"","*":"Sanofi Pasteur"},{"ns":0,"exists":"","*":"Shingrix"},{"ns":0,"exists":"","*":"Southern Illinois University School of Medicine"},{"ns":0,"exists":"","*":"T-cell"},{"ns":0,"exists":"","*":"Temple University"},{"ns":0,"exists":"","*":"Transfected"},{"ns":0,"exists":"","*":"Tumors"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"University Medical Center Utrecht"},{"ns":0,"exists":"","*":"University of California, San Diego"},{"ns":0,"exists":"","*":"Valaciclovir"},{"ns":0,"exists":"","*":"Varicella vaccine"},{"ns":0,"exists":"","*":"Varicella zoster virus"},{"ns":0,"exists":"","*":"Varivax"},{"ns":0,"exists":"","*":"Viral shedding"},{"ns":0,"exists":"","*":"Viral vector"},{"ns":0,"exists":"","*":"Worcester"},{"ns":0,"exists":"","*":"Zinc finger nuclease"},{"ns":0,"exists":"","*":"Zostavax"},{"ns":0,"exists":"","*":"Zurich"},{"ns":0,"*":"Rational Vaccines"},{"ns":0,"*":"Admedus"},{"ns":0,"*":"Immune Design"},{"ns":0,"*":"GenVec"},{"ns":0,"*":"Vitaherpavac"},{"ns":0,"*":"Herpovax"},{"ns":0,"*":"Profectus BioSciences"},{"ns":0,"*":"Tomegavax"},{"ns":0,"*":"Coridon (company)"},{"ns":0,"*":"Admedus Vaccines"},{"ns":0,"*":"NanoBio Corporation"},{"ns":0,"*":"Biomedical Research Models"},{"ns":0,"*":"Vir Biotechnology"},{"ns":0,"*":"Redbiotec"},{"ns":0,"*":"BioVex"},{"ns":0,"*":"Genocea"},{"ns":0,"*":"AuRx"},{"ns":0,"*":"Cantab Pharmaceuticals"},{"ns":0,"*":"Mymetics"},{"ns":0,"*":"Vical"},{"ns":0,"*":"ImmunoVEX"},{"ns":0,"*":"HerpV"},{"ns":0,"*":"Genocea Biosciences"},{"ns":0,"*":"ICP4"},{"ns":0,"*":"Vaxfectin"},{"ns":0,"*":"BX795"},{"ns":0,"*":"Intercellular"}],"templates":[{"ns":10,"exists":"","*":"Template:As of"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg","HalfordsVac.jpg","HSV529.png"],"externallinks":["//www.ncbi.nlm.nih.gov/pmc/articles/PMC3324142","//doi.org/10.1155/2012/187585","//www.ncbi.nlm.nih.gov/pubmed/22548113","//www.ncbi.nlm.nih.gov/pmc/articles/PMC151069","//doi.org/10.1172/JCI16126","//www.ncbi.nlm.nih.gov/pubmed/12122103","https://liveherpesvaccine.com/rational-vaccines-inc/","https://liveherpesvaccine.com/","http://medcitynews.com/2017/03/rational-vaccines-pharma-deregulation/","https://www.cnn.com/2018/04/23/health/fda-halford-herpes-vaccine-research/index.html","http://knipelab.med.harvard.edu/","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5630753","http://www.admedus.com/au/technology/immunotherapies/","http://www.admedus.com/us/health-solutions/research-development/","http://clients2.weblink.com.au/news/pdf_1%5C01791053.pdf","https://news.feinberg.northwestern.edu/2017/12/herpes-virus-mutant-points-towards-new-vaccine-strategy/","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5749899","//doi.org/10.1371/journal.ppat.1006741","//www.ncbi.nlm.nih.gov/pubmed/29216315","http://insight.jci.org/articles/view/88529","//doi.org/10.1172/jci.insight.88529","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4985247","//www.ncbi.nlm.nih.gov/pubmed/27536733","https://www.pennmedicine.org/news/news-releases/2017/january/new-genital-herpes-vaccine-candidate-provides-powerful-protection-in-preclinical-tests","http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006141","//doi.org/10.1371/journal.ppat.1006141","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5245903","//www.ncbi.nlm.nih.gov/pubmed/28103319","http://www.immunedesign.com/pipeline/","//doi.org/10.1016/j.vaccine.2015.10.137","//www.ncbi.nlm.nih.gov/pubmed/26571309","http://www.genvec.com/product-pipeline/gv2207-hsv-2-immunotherapeutic","http://www.nanobio.com/vaccine-pipeline/hsv-2-vaccine/","http://www.prnewswire.com/news-releases/nanobios-genital-herpes-vaccine-demonstrates-efficacy-in-guinea-pigs-as-both-a-prophylactic-and-a-therapeutic-vaccine-300147057.html","http://www.profectusbiosciences.com/pipeline/pbsvax.html#hsv-2","https://www.merckvaccines.com/Products/Zostavax/efficacy/","https://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf","https://au.gsk.com/media/216354/varilrix_cmi_au_007_approved.pdf","http://www.who.int/wer/2014/wer8925.pdf","http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3956","http://www.nature.com/cti/journal/v5/n7/full/cti201644a.html","//doi.org/10.1038/cti.2016.44","//www.ncbi.nlm.nih.gov/pubmed/27525067","http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004336/human_med_002240.jsp&mid=WC0b01ac058001d124","http://www.philly.com/philly/business/glaxosmithkline-reports-positive-results-with-its-shingles-vaccine-20170622.html","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3055896","http://adsabs.harvard.edu/abs/2011PLoSO...617748H","//doi.org/10.1371/journal.pone.0017748","//www.ncbi.nlm.nih.gov/pubmed/21412438","http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0065523","http://adsabs.harvard.edu/abs/2013PLoSO...865523H","//doi.org/10.1371/journal.pone.0065523","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3675040","//www.ncbi.nlm.nih.gov/pubmed/23755244","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012251","http://adsabs.harvard.edu/abs/2010PLoSO...512251H","//doi.org/10.1371/journal.pone.0012251","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2923193","//www.ncbi.nlm.nih.gov/pubmed/20808928","http://www.sj-r.com/news/20170703/herpes-vaccine-trials-to-continue-after-siu-med-school-scientists-death","https://www.acsh.org/news/2018/02/08/i-met-theravax-herpes-vaccine-patient-and-here-what-he-said-12543","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3582571","http://adsabs.harvard.edu/abs/2013PLoSO...857224M","//doi.org/10.1371/journal.pone.0057224","//www.ncbi.nlm.nih.gov/pubmed/23468943","http://knipelab.med.harvard.edu/pdfs/2007van%20Lint%20et%20al.pdf","http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HSV11-8-13.aspx","http://knipelab.med.harvard.edu/pdfs/Hoshino_etal_2005_JV.pdf","http://archives.focus.hms.harvard.edu/2008/030708/licensing.shtml","http://ir.immunedesign.com/releasedetail.cfm?ReleaseID=876534","https://clinicaltrials.gov/ct2/show/NCT01915212","http://www.hsvoutbreak.com/potential-cure-for-the-herpes-simplex-virus","http://www.couriermail.com.au/news/queensland/gardasil-inventor-professor-ian-frazers-new-genital-herpes-vaccine-proves-safe-in-passing-first-human-trials/story-fnihsrf2-1226817096262","http://www.proactiveinvestors.com.au/companies/news/57916/admedus-vaccine-for-herpes-has-success-moves-to-next-clinical-trial-57916.html","http://www.proactiveinvestors.com.au/companies/news/56472/admedus-increases-interest-in-prof-ian-frazers-vaccines-56472.html","http://www.proactiveinvestors.com.au/companies/news/61686/admedus-has-high-hopes-for-herpes-vaccine-as-dosing-commences-61686.html","http://clients2.weblink.com.au/news/pdf_2%5C01791053.pdf","http://elifesciences.org/content/4/e06054","http://www.hhmi.org/news/radical-vaccine-design-effective-against-herpes-viruses","http://www.nanobio.com/GenitalHerpesProphylacticTherapeuticVaccine.html","http://www.vaccinenation.org/2014/06/10/biomedical-research-models-inc-brm-awarded-3-0-million-nih-grant-advance-mucosal-hsv-2-vaccine-towards-clinical-trials/","https://projectreporter.nih.gov/project_info_description.cfm?aid=8713366&icde=0","http://www.who.int/immunization/research/meetings_workshops/HSV_vaccineRD_Sept2014.pdf","https://www.niaid.nih.gov/news-events/genital-herpes-vaccine-moderately-protective-against-one-two-herpes-viruses","http://adsabs.harvard.edu/abs/2010Sci...330..304C","//doi.org/10.1126/science.330.6002.304","//www.ncbi.nlm.nih.gov/pubmed/20947733","http://www.paxvax.com/about/news/paxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus","http://www.paxvax.com/about","http://www.paxvax.com/the-paxvax-solution/product-pipeline","http://jvi.asm.org/content/86/8/4586.full","http://www.amgen.com/science/pipe.html","https://web.archive.org/web/20170926075918/http://ir.genocea.com/releasedetail.cfm?ReleaseID=1041589","http://ir.genocea.com/releasedetail.cfm?ReleaseID=1041589","http://www.aurx.com/herpes.htm","http://www.aurx.com/herpes2.htm","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4385587","//doi.org/10.1586/14760584.2014.932694","//www.ncbi.nlm.nih.gov/pubmed/25077372","http://www.mymetics.com/vaccine-pipeline/herpes-simplex/","https://clinicaltrials.gov/ct2/show/NCT01687595?term=HerpV&rank=1","http://www.vical.com/products/HSV-2-vaccine/default.aspx","http://www.vical.com/investors/news-releases/News-Release-Details/2018/Vical-Reports-Phase-2-Trial-of-HSV-2-Therapeutic-Vaccine-Did-Not-Meet-Primary-Endpoint/default.aspx","https://web.archive.org/web/20071020035054/http://www.niaid.nih.gov/dmid/stds/herpevac/studyover_faqs.htm","http://www.niaid.nih.gov/dmid/stds/herpevac/studyover_faqs.htm","http://paxvax.com/about/news/paxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus","http://www.news-medical.net/news/20100304/BioVex-commences-dosing-in-Phase-1-study-of-ImmunoVEX-live-attenuated-genital-herpes-vaccine.aspx","http://www.boston.com/business/healthcare/articles/2011/03/04/amgen_completes_acquisition_of_biovex_group/","http://www.aurx.com/pressrelease013.htm","http://www.businesswire.com/news/home/20140626005211/en/Agenus-Vaccine-Shows-Significant-Reduction-Viral-Burden","http://justherpes.com/herpes-news/herpes-news-2014/","http://agenusbio.com/pipeline/","http://www.genocea.com/assets/vanWagoner_GEN003_IDWeek2015_poster_presented_09Oct2015.pdf","http://www.streetinsider.com/Corporate+News/Vical+(VICL)+Genital+Herpes+Vaccine+Phase+12+Missed+Primary+Endpoint/10669728.html","http://www.fiercebiotech.com/press-releases/vical-reports-top-line-results-phase-12-trial-therapeutic-genital-herpes-va","https://globenewswire.com/news-release/2016/06/20/849939/0/en/Vical-s-Phase-1-2-Trial-Data-Presented-at-ASM-2016-Shows-Bivalent-Vaccine-Imparts-Reduction-in-Genital-Herpes-Lesions-Durable-to-9-Months.html","http://www.annualreviews.org/doi/10.1146/annurev-med-051215-031129","//doi.org/10.1146/annurev-med-051215-031129","//www.ncbi.nlm.nih.gov/pubmed/27576009","https://insight.jci.org/articles/view/88468","//doi.org/10.1172/jci.insight.88468","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5026126","//www.ncbi.nlm.nih.gov/pubmed/27642635","http://www.fredhutch.org/en/news/center-news/2016/09/can-gene-editing-cure-herpes.html","http://www.sciencedirect.com/science/article/pii/S0042682215000707","//doi.org/10.1016/j.virol.2015.02.024","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4424069","//www.ncbi.nlm.nih.gov/pubmed/25759096","http://www.nature.com/articles/srep23146","http://adsabs.harvard.edu/abs/2016NatSR...623146R","//doi.org/10.1038/srep23146","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4827394","//www.ncbi.nlm.nih.gov/pubmed/27064617","http://temple-news.com/news/researchers-aim-to-find-cure-for-herpes/","http://www.excisionbio.com/pipeline","http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005701","//doi.org/10.1371/journal.ppat.1005701","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4928872","//www.ncbi.nlm.nih.gov/pubmed/27362483","http://blogs.plos.org/speakingofmedicine/2016/08/04/crispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation/","http://www.aicuris.com/29/Research-Development/R-D-Pipeline.htm","//doi.org/10.3390/molecules16097210","//www.ncbi.nlm.nih.gov/pubmed/21869749","http://www.nature.com/mt/journal/v13/n1s/abs/mt2006942a.html","https://web.archive.org/web/20100613031337/http://news.ufl.edu/2009/02/03/herpes-2/","http://news.ufl.edu/2009/02/03/herpes-2/","https://www.youtube.com/watch?v=lQaWh8VLkiU&feature=youtu.be","https://www.reuters.com/article/idUSN0229815620080702?pageNumber=2&virtualBrandChannel=0","http://www.time.com/time/health/article/0,8599,1819739,00.html","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2871293","//doi.org/10.1158/1535-7163.MCT-09-0110","//www.ncbi.nlm.nih.gov/pubmed/19671758","//www.ncbi.nlm.nih.gov/pmc/articles/PMC39867","http://adsabs.harvard.edu/abs/1996PNAS...93.1831M","//doi.org/10.1073/pnas.93.5.1831","//www.ncbi.nlm.nih.gov/pubmed/8700844","//www.ncbi.nlm.nih.gov/pmc/articles/PMC515626","//www.ncbi.nlm.nih.gov/pubmed/191652","http://www.nature.com/onc/journal/v25/n46/full/1209912a.html","//doi.org/10.1038/sj.onc.1209912","//www.ncbi.nlm.nih.gov/pubmed/17028597","http://www.redbiotec.ch/product/hsv-2/","http://news.feinberg.northwestern.edu/2017/12/herpes-virus-mutant-points-towards-new-vaccine-strategy/","http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0076407","http://www.clinicaltrials.gov/ct2/show/NCT02114060","http://medicalresearch.com/author-interviews/first-therapeutic-vaccine-genital-herpes-shows-promise/22945/","https://clinicaltrials.gov/ct2/show/NCT02515175","http://www.clinicaltrials.gov/ct/show/NCT02030301","https://www.clinicaltrials.gov/ct/show/NCT02837575","http://research.fhcrc.org/jerome/en.html","http://www.sciencedirect.com/science/article/pii/S0264410X16002978"],"sections":[{"toclevel":1,"level":"2","line":"Vaccine research","number":"1","index":"1","fromtitle":"Herpes_simplex_research","byteoffset":502,"anchor":"Vaccine_research"},{"toclevel":1,"level":"2","line":"Vaccine candidate","number":"2","index":"2","fromtitle":"Herpes_simplex_research","byteoffset":2490,"anchor":"Vaccine_candidate"},{"toclevel":2,"level":"3","line":"Attenuated vaccines","number":"2.1","index":"3","fromtitle":"Herpes_simplex_research","byteoffset":13448,"anchor":"Attenuated_vaccines"},{"toclevel":3,"level":"4","line":"Live, attenuated variant of the HSV-2 vaccine","number":"2.1.1","index":"4","fromtitle":"Herpes_simplex_research","byteoffset":13914,"anchor":"Live,_attenuated_variant_of_the_HSV-2_vaccine"},{"toclevel":3,"level":"4","line":"Replication-defective HSV-2 vaccine","number":"2.1.2","index":"5","fromtitle":"Herpes_simplex_research","byteoffset":17734,"anchor":"Replication-defective_HSV-2_vaccine"},{"toclevel":2,"level":"3","line":"Glycoprotein gD- and DNA-based vaccines","number":"2.2","index":"6","fromtitle":"Herpes_simplex_research","byteoffset":21191,"anchor":"Glycoprotein_gD-_and_DNA-based_vaccines"},{"toclevel":3,"level":"4","line":"Admedus's vaccine","number":"2.2.1","index":"7","fromtitle":"Herpes_simplex_research","byteoffset":21240,"anchor":"Admedus's_vaccine"},{"toclevel":2,"level":"3","line":"Other vaccine exploration","number":"2.3","index":"8","fromtitle":"Herpes_simplex_research","byteoffset":25071,"anchor":"Other_vaccine_exploration"},{"toclevel":2,"level":"3","line":"Discontinued vaccines","number":"2.4","index":"9","fromtitle":"Herpes_simplex_research","byteoffset":29098,"anchor":"Discontinued_vaccines"},{"toclevel":3,"level":"4","line":"Detailed Information on discontinued vaccines","number":"2.4.1","index":"10","fromtitle":"Herpes_simplex_research","byteoffset":34690,"anchor":"Detailed_Information_on_discontinued_vaccines"},{"toclevel":1,"level":"2","line":"Genome editing","number":"3","index":"11","fromtitle":"Herpes_simplex_research","byteoffset":43306,"anchor":"Genome_editing"},{"toclevel":2,"level":"3","line":"Notable research","number":"3.1","index":"12","fromtitle":"Herpes_simplex_research","byteoffset":43966,"anchor":"Notable_research"},{"toclevel":1,"level":"2","line":"Herpes simplex virus","number":"4","index":"13","fromtitle":"Herpes_simplex_research","byteoffset":48225,"anchor":"Herpes_simplex_virus"},{"toclevel":2,"level":"3","line":"Pharmaceutical drugs","number":"4.1","index":"14","fromtitle":"Herpes_simplex_research","byteoffset":48430,"anchor":"Pharmaceutical_drugs"},{"toclevel":2,"level":"3","line":"Notable progress","number":"4.2","index":"15","fromtitle":"Herpes_simplex_research","byteoffset":50616,"anchor":"Notable_progress"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"16","fromtitle":"Herpes_simplex_research","byteoffset":59992,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Herpes simplex research","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q5743645"}]}}